Data / Research funding / Hepatitis
Hepatitis: 962 NIH awards ($1.9B) to 265 organizations
962 NIH awards ($1.9B) in the NIH spending category Hepatitis, to 265 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 962 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $472,070,715 | December 1, 2024 | November 30, 2025 | CURRIER, JUDITH S. | reporter.nih.gov |
| AIDS Clinical Trial Group Laboratory Center | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $56,714,107 | January 1, 2014 | November 30, 2027 | ALDROVANDI, GRACE M | reporter.nih.gov |
| University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $24,477,809 | February 1, 2007 | November 30, 2027 | ERON, JOSEPH J | reporter.nih.gov |
| UCLA AIDS Prevention and Treatment Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,546,764 | February 1, 2007 | November 30, 2027 | LANDOVITZ, RAPHAEL J | reporter.nih.gov |
| Boston HIV CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,445,869 | January 15, 2007 | November 30, 2027 | KURITZKES, DANIEL R. | reporter.nih.gov |
| Expanding HOPE Liver Transplantation: Understanding Opportunistic Infection and Cancer Risk | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $18,807,472 | August 1, 2018 | August 31, 2030 | DURAND, CHRISTINE MARIE | reporter.nih.gov |
| NIAID VIROLOGY QUALITY ASSURANCE (VQA) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $17,732,468 | June 21, 2025 | June 20, 2026 | DENNY, THOMAS | reporter.nih.gov |
| International epidemiology Databases to Evaluate AIDS (IeDEA) Southern Africa. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,840,939 | May 1, 2025 | April 30, 2027 | ROHNER, ELIANE | reporter.nih.gov |
| Center for Cellular Metabolism Research in Oklahoma | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $15,159,612 | February 5, 2021 | January 31, 2027 | XIA, LIJUN | reporter.nih.gov |
| Pitt-Ohio State Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,065,770 | February 1, 2007 | November 30, 2027 | RIDDLER, SHARON | reporter.nih.gov |
| Hepatobiology and Toxicology COBRE | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $12,863,981 | June 10, 2016 | March 31, 2027 | MCCLAIN, CRAIG J. | reporter.nih.gov |
| Vanderbilt HIV Clinical Trials Unit (CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,733,650 | February 1, 2007 | November 30, 2027 | HAAS, DAVID W | reporter.nih.gov |
| CURE CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,461,433 | January 1, 2007 | November 30, 2027 | SPECTOR, STEPHEN A | reporter.nih.gov |
| AIDS Linked to the IntraVenous Experience (ALIVE) Study | NIH | National Institute on Drug Abuse | 2021 to 2025 | $12,226,379 | January 1, 2014 | May 31, 2030 | MEHTA, SHRUTI H | reporter.nih.gov |
| Durable Alteration of the Human Immune system after Infection or Immunotherapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,785,761 | June 8, 2009 | May 31, 2029 | CHUNG, RAYMOND T | reporter.nih.gov |
| Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD) - Indiana University Data Coordinating Center | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $11,773,646 | August 1, 2018 | June 30, 2029 | TU, WANZHU | reporter.nih.gov |
| Mays Cancer Center at UT Health SA | NIH | National Cancer Institute | 2021 to 2025 | $11,193,809 | August 1, 1997 | July 31, 2026 | ZHENG, LEI | reporter.nih.gov |
| Reagent Program for HIV and other Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,735,388 | October 15, 2023 | January 13, 2024 | RASHID, SUJATHA | reporter.nih.gov |
| Addressing risk through Community Treatment for Infectious disease and Opioid use disorder Now (ACTION) among justice-involved populations | NIH | National Institute on Drug Abuse | 2021 to 2025 | $10,550,278 | September 30, 2020 | July 31, 2026 | SPRINGER, SANDRA ANN | reporter.nih.gov |
| Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,070,868 | March 15, 2007 | November 30, 2027 | SUPPARATPINYO, KHUANCHAI | reporter.nih.gov |
| Southern Liver Health Cohort | NIH | National Cancer Institute | 2023 to 2025 | $10,038,112 | September 21, 2021 | August 31, 2027 | HOYO, CATHRINE | reporter.nih.gov |
| The Johns Hopkins University - Uganda Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,910,249 | February 5, 2007 | November 30, 2027 | FOWLER, MARY GLENN | reporter.nih.gov |
| Health Economics of Substance Use Disorder, HCV, and HIV Treatment: Supporting Financial Sustainability, Advanced Methods, and Knowledge Translation | NIH | National Institute on Drug Abuse | 2021 to 2025 | $8,690,640 | July 15, 2015 | April 30, 2030 | SCHACKMAN, BRUCE R | reporter.nih.gov |
| Data Coordinating Center for the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Continuation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $8,663,508 | May 1, 2002 | June 30, 2028 | SHADE, DAVID M | reporter.nih.gov |
| The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,239,326 | January 15, 2008 | November 30, 2027 | GRINSZTEJN, BEATRIZ | reporter.nih.gov |
| A trial of transplanting Hepatitis C-viremic kidneys into Hepatitis C-Negative kidney recipients (THINKER-NEXT) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $7,767,541 | April 15, 2021 | March 31, 2027 | SCHAUBEL, DOUGLAS EARL | reporter.nih.gov |
| Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism | NIH | National Institute on Drug Abuse | 2021 to 2024 | $6,868,774 | April 1, 2020 | January 31, 2026 | STRATHDEE, STEFFANIE A. | reporter.nih.gov |
| Ancillary Studies of NAFLD and NASH in HIV infected Adults | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $6,132,391 | March 21, 2020 | January 31, 2026 | CHALASANI, NAGA P | reporter.nih.gov |
| Johns Hopkins HIV Clinical Cohort | NIH | National Institute on Drug Abuse | 2021 to 2024 | $5,955,256 | July 1, 2014 | March 31, 2026 | MOORE, RICHARD DOUGLAS | reporter.nih.gov |
| Rational design and efficacy testing of vaccines against HCV | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,737,237 | May 5, 2022 | April 30, 2027 | FUERST, THOMAS R | reporter.nih.gov |
| Improvements to the Regional Biocontainment Research Facilities at the University of Missouri | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $5,667,997 | September 23, 2021 | February 28, 2025 | LORSON, CHRISTIAN L. | reporter.nih.gov |
| Chicago Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,330,849 | February 1, 2007 | November 30, 2027 | ACHENBACH, CHAD J | reporter.nih.gov |
| A Randomized Controlled Trial of Prophylaxis with Direct-acting Antivirals for Kidney Transplantation from Hepatitis C virus-infected donor to Uninfected Recipients (PREVENT-HCV) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,162,956 | March 25, 2022 | February 28, 2027 | DURAND, CHRISTINE MARIE | reporter.nih.gov |
| High-throughput proteomics using submicroliter amounts of plasma for comprehensive assessment of the immune status | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,147,391 | April 9, 2020 | March 31, 2026 | STEEN, HANNO | reporter.nih.gov |
| Integrating Addiction and Infectious Diseases Services into Primary Care in Rural Settings | NIH | National Institute on Drug Abuse | 2021 to 2025 | $4,664,222 | August 1, 2021 | May 31, 2027 | ALTICE, FREDERICK LEWIS | reporter.nih.gov |
| Non-alcoholic Fatty Liver Disease and Cardiovascular Disease in Hispanics/Latinos | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $4,589,716 | September 1, 2019 | August 31, 2024 | KIZER, JORGE R | reporter.nih.gov |
| Increasing Access to Hepatitis C Treatment in Opioid Endemic Rural Areas: the Kentucky Viral Hepatitis Treatment (KeY Treat) Study | NIH | National Institute on Drug Abuse | 2021 to 2023 | $4,371,481 | September 30, 2018 | July 31, 2025 | HAVENS, JENNIFER R | reporter.nih.gov |
| The Long-Acting/Extended Release Antiretroviral Resource Program (LEAP) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,204,220 | May 15, 2015 | June 30, 2030 | FLEXNER, CHARLES W. | reporter.nih.gov |
| Integrating HCV services into HIV programs for PWID in India | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,184,487 | July 8, 2019 | June 30, 2025 | MEHTA, SHRUTI H | reporter.nih.gov |
| RADx Innovation Funnel for Hepatitis B Diagnostics - Coordination Center | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $4,074,004 | September 30, 2024 | September 29, 2026 | SCHACHTER, STEVEN C. | reporter.nih.gov |
| A novel diagnostic Kit for Hepatocellular Carcinoma | NIH | National Cancer Institute | 2021 to 2023 | $3,993,675 | September 1, 2012 | August 31, 2025 | LU, XUANYONG | reporter.nih.gov |
| A systems immunology approach for predicting poor responses to Hepatitis B vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,925,255 | September 17, 2021 | August 31, 2026 | HERATI, RAMIN | reporter.nih.gov |
| Making Better Decisions: Policy Modeling for AIDS and Drug Abuse | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,865,844 | September 25, 2022 | January 31, 2029 | OWENS, DOUGLAS K | reporter.nih.gov |
| A Rhesus Macaque Model of HIV and HBV co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,842,980 | March 20, 2021 | February 28, 2026 | BURWITZ, BENJAMIN J | reporter.nih.gov |
| Spatio-temporal Methods for Surveillance of the Opioid Syndemic | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,748,657 | September 1, 2025 | August 31, 2029 | KLINE, DAVID M | reporter.nih.gov |
| Pathogenesis of youth onset pre-diabetes and Type 2 diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,716,431 | September 22, 2016 | July 31, 2026 | CAPRIO, SONIA | reporter.nih.gov |
| Conduct Synthesis and Acquire Batches of Compounds for Subsequent Biological In Vitro and In Vivo Testing | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,702,250 | April 1, 2024 | March 31, 2025 | MIDDLETON, MARK | reporter.nih.gov |
| Novel Determinants for Progression of Non-Alcoholic Fatty Liver Disease to Hepatocellular Carcinoma and Other Health Outcomes | NIH | National Cancer Institute | 2021 to 2025 | $3,678,371 | September 7, 2021 | August 31, 2026 | YUAN, JIAN-MIN | reporter.nih.gov |
| Estrogen Administration for the Treatment of NASH in Postmenopausal Women | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,638,994 | August 1, 2021 | May 31, 2027 | MILLER, KAREN K | reporter.nih.gov |
| Clinical & Immunological Study of Treatment Withdrawal in E-Ag Negative Hepatitis B | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,618,437 | September 1, 2016 | June 30, 2026 | COOPER, STEWART | reporter.nih.gov |
| NIH: Spatial Models of Intrahepatic Hepatitis Virus Propagation in Humans | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,593,236 | February 7, 2022 | January 31, 2027 | RIBEIRO, RUY M | reporter.nih.gov |
| Assessing the effects of oral pre-exposure prophylaxis on pharmacokinetics of monoclonal and vaccine-induced antibodies among women vulnerable to HIV-1 | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,554,273 | September 12, 2025 | August 31, 2029 | HUANG, YUNDA | reporter.nih.gov |
| Interactions between neutrophils and cholangiocytes in alcoholic hepatitis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $3,548,231 | September 25, 2021 | June 30, 2027 | NATHANSON, MICHAEL H | reporter.nih.gov |
| Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,515,317 | August 1, 2006 | July 31, 2026 | KAY, MARK A | reporter.nih.gov |
| Structural and Mechanistic basis for RNA Silencing | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,507,599 | August 1, 2018 | July 31, 2028 | MACRAE, IAN JOHN | reporter.nih.gov |
| Clinical Research on Nonalcoholic Fatty Liver Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,430,513 | September 15, 2002 | June 30, 2027 | LOOMBA, ROHIT | reporter.nih.gov |
| Human Genetic determinants of HBV recovery | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,412,348 | September 30, 1999 | December 31, 2026 | THOMAS, DAVID L | reporter.nih.gov |
| Combating Related Epidemics in HCV through Simplified Testing and Treatment (CREST) | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,411,692 | September 24, 2025 | August 31, 2030 | NAGGIE, SUSANNA | reporter.nih.gov |
| Evaluation of a community-based education, navigation, and support (CENS) intervention to reduce opioid-related harms among military veterans | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,379,762 | September 30, 2021 | July 31, 2027 | BENNETT, ALEXANDER S | reporter.nih.gov |
| Promoting remote and secondary risk prevention services in rural settings | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,349,340 | September 30, 2022 | July 31, 2027 | PHO, MAI TUYET | reporter.nih.gov |
| Immunologic correlates of functional cure of HBV with immune checkpoint blockade | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,338,136 | May 22, 2020 | April 30, 2026 | LAUER, GEORG MICHAEL | reporter.nih.gov |
| A geospatial analysis of hotspots and targeted injection settings pilot intervention for HIV prevention among people who inject drugs in Baltimore, Maryland | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,292,995 | July 1, 2020 | May 31, 2027 | LATKIN, CARL A | reporter.nih.gov |
| A smartphone-enabled point-of-care HCV Ag diagnostic using catalytic nanoparticles and AI-enhanced image processing | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $3,284,055 | September 9, 2022 | June 30, 2027 | SHAFIEE, HADI | reporter.nih.gov |
| IL-27R signaling as a negative regulator of innate and adaptive anti-cancer immunity in hepatocellular carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $3,273,154 | August 1, 2022 | July 31, 2027 | KOLTSOVA, EKATERINA | reporter.nih.gov |
| Longitudinal Study of Early NAFLD Progression and the Gut Microbiome in Asian Americans, Native Hawaiians and Whites | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2025 | $3,263,901 | September 26, 2022 | June 30, 2027 | LIM, UNHEE | reporter.nih.gov |
| Lead optimization of Hepatitis B Virus ribonuclease H inhibitors | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,253,243 | December 1, 2020 | November 30, 2026 | TAVIS, JOHN E | reporter.nih.gov |
| Implementation of telemedicine and social network driven HIV service uptake for comprehensive HIV service integration in rural syringe service programs | NIH | National Institute on Drug Abuse | 2023 to 2025 | $3,234,132 | August 1, 2023 | May 31, 2028 | FALADE-NWULIA, OLUWASEUN | reporter.nih.gov |
| Examine Individual and Clinical Factors Affecting Liver Disease Management | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2025 | $3,219,854 | September 15, 2022 | May 31, 2027 | MA, GRACE X. | reporter.nih.gov |
| Extracellular Vesicle-Based Digital Scoring Assay for Detecting Early-stage Hepatocellular Carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $3,197,232 | January 18, 2021 | December 31, 2026 | ZHU, YAZHEN | reporter.nih.gov |
| Neutralizing antibody responses during natural control of acute hepatitis B with and without HIV-1 coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,186,484 | August 1, 2022 | July 31, 2027 | BAILEY, JUSTIN RICHARD | reporter.nih.gov |
| Collaborative Integration of HCV Molecular Virology and Mathematical Modeling | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,185,361 | August 1, 2010 | May 31, 2027 | UPRICHARD, SUSAN L. | reporter.nih.gov |
| Intestinal proteases in alcohol-associated liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2025 | $3,182,397 | September 20, 2025 | August 31, 2029 | SCHNABL, BERND G. | reporter.nih.gov |
| Novel macrophage mediated signals regulate the immunoregulatory environment of the neonatal liver | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $3,176,680 | September 15, 2025 | September 14, 2029 | NIJAGAL, AMAR | reporter.nih.gov |
| CTRP and Metabolic Control | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,168,077 | July 15, 2010 | June 30, 2028 | WONG, GUANG WILLIAM | reporter.nih.gov |
| Launching HBV with RNA to assess antiviral resistance and explore fundamental aspects of virus-host biology | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,156,556 | February 10, 2020 | April 30, 2030 | RICE, CHARLES M | reporter.nih.gov |
| Extracellular vesicle cargo and risk of NAFLD and NASH in U.S. youth | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $3,153,279 | April 15, 2022 | February 28, 2027 | DISTEFANO, JOHANNA K | reporter.nih.gov |
| Impact of harm reduction care in HIV clinical settings on stigma and health outcomes for PLWH who use drugs | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,152,106 | September 30, 2021 | June 30, 2027 | HAWK, MARY ELIZABETH | reporter.nih.gov |
| Molecular and structural characterization of broadly neutralizing anti-HCV antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,115,747 | February 15, 2023 | January 31, 2028 | BAILEY, JUSTIN RICHARD | reporter.nih.gov |
| Epigenetics of human Hepatic Stellate Cells (HSCs) in NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,103,795 | May 15, 2014 | August 31, 2027 | KISSELEVA, TATIANA | reporter.nih.gov |
| The Impact of HCV Treatment in HIV/HCV coinfected and HCV monoinfected Incarcerated Persons on HCV Elimination | NIH | National Institute on Drug Abuse | 2021 to 2024 | $3,045,888 | September 30, 2020 | August 31, 2025 | IRVIN, RISHA | reporter.nih.gov |
| GMP MANUFACTURE OF CLINICAL GRADE THERAPEUTIC VACCINE FOR THE TREATMENT OF PATIENTS WITH CHRONIC HBV | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $3,034,670 | June 5, 2018 | March 31, 2025 | NAKAAR, VALERIAN | reporter.nih.gov |
| A Randomized Trial to Test the Efficacy of a Partner Navigation Intervention for HCV Treatment among Young Adult People who Inject Drugs | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,017,588 | June 1, 2022 | March 31, 2027 | MORRIS, MEGHAN D | reporter.nih.gov |
| Analysis of Chemical Structures and Therapeutic Activity of Agents for HIV, TB, and HBV (CHEMDB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,016,918 | September 30, 2024 | September 29, 2025 | SUMNER, LOUISE | reporter.nih.gov |
| Multi-level Evaluation of Racial/ethnic Disparities in Liver Disease Outcomes | NIH | National Cancer Institute | 2021 to 2025 | $3,010,755 | March 18, 2021 | February 28, 2027 | KANWAL, FASIHA | reporter.nih.gov |
| Mechanisms of T Cell Quiescence and Exhaustion | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,001,713 | March 1, 2019 | February 28, 2029 | SARKAR, SUROJIT | reporter.nih.gov |
| Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,000,000 | May 24, 2021 | April 30, 2025 | COBURN, GLEN ANDREW | reporter.nih.gov |
| Targeting hepatitis B virus cccDNA during HBV/HIV co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,993,820 | August 20, 2024 | July 31, 2029 | PLOSS, ALEXANDER | reporter.nih.gov |
| Molecular Magnetic Resonance of Hepatic Fibrogenesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,974,604 | July 3, 2019 | March 31, 2028 | CARAVAN, PETER D | reporter.nih.gov |
| Anchimerically Activatable Anti-Zika/Dengue ProTides | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,946,770 | August 1, 2021 | July 31, 2026 | WAGNER, CARSTON R. | reporter.nih.gov |
| Novel IL-23 inhibitor for the treatment of alcohol associated liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $2,935,798 | September 20, 2020 | August 31, 2025 | LOOMBA, ROHIT | reporter.nih.gov |
| Moderately CHO-restricted diet as treatment targeting improvement in hepatic lipid and insulin sensitivity in adolescents with NAFLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,928,802 | May 5, 2021 | July 31, 2026 | GOSS, AMY MISKIMON | reporter.nih.gov |
| Dynamic Strategies for the clinical management of HIV disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,926,858 | August 9, 2012 | May 31, 2028 | HERNAN, MIGUEL | reporter.nih.gov |
| Kinetic and structural basis for SARS-CoV-2 RNA-dependent RNA polymerase specificity and inhibition | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,889,190 | July 16, 2021 | June 30, 2027 | JOHNSON, KENNETH ALLEN | reporter.nih.gov |
| Non-invasive etiology-adjusted precision liver cancer risk prediction | NIH | National Cancer Institute | 2025 | $2,876,456 | August 5, 2025 | July 31, 2029 | HOSHIDA, YUJIN | reporter.nih.gov |
| Cardiovascular Risk Reduction in an Aging HIV-Infected Population: The Impact of HCV Co-Infection | NIH | National Institute on Aging | 2021 to 2023 | $2,851,326 | May 1, 2019 | January 31, 2025 | TRIANT, VIRGINIA ATHENA | reporter.nih.gov |
| Clinical Resource for Alcoholic Hepatitis Inestigation | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,850,908 | August 1, 2016 | April 30, 2027 | SUN, ZHAOLI | reporter.nih.gov |
| Computational modeling for HCV vaccine trial design and optimal vaccine-based combination interventions | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,842,189 | November 1, 2021 | October 31, 2026 | DAHARI, HAREL | reporter.nih.gov |
| Cooperative mechanisms of HIV-enhanced liver fibrogenesis in HBV Coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,836,440 | July 15, 2020 | June 30, 2027 | CHUNG, RAYMOND T | reporter.nih.gov |
| Significance and mechanisms of hepatic ChREBPα induction via post-translational modifications in diet-induced NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,830,469 | April 1, 2014 | May 31, 2027 | YIN, LEI | reporter.nih.gov |
| Data-Driven Mathematical and Computational Modeling of Hepatitis D Infection and Treatment Response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,802,377 | February 15, 2020 | January 31, 2026 | DAHARI, HAREL | reporter.nih.gov |
| Selective mTORC1 inhibition to prevent and treat NAFLD and NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,795,850 | July 15, 2016 | May 31, 2026 | ARANY, ZOLTAN P | reporter.nih.gov |
| Novel Biomarkers for Post-Liver Transplant NASH Fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,777,764 | July 18, 2022 | May 31, 2027 | ARTEEL, GAVIN E | reporter.nih.gov |
| Targeting hepatic mitochondrial function in humans with NAFLD using insulin sensitizers | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,715,093 | April 15, 2022 | March 31, 2027 | NORTON, LUKE | reporter.nih.gov |
| Jagged-Notch signaling in NASH/fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,685,447 | February 15, 2019 | June 30, 2028 | PAJVANI, UTPAL | reporter.nih.gov |
| Spinal cord injury causes liver pathology and metabolic dysfunction | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,668,295 | April 1, 2021 | March 31, 2027 | MCTIGUE, DANA M | reporter.nih.gov |
| Mechanisms of Advanced NAFLD Disparities in Hispanics: A Multi-level Analysis | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2025 | $2,655,656 | January 1, 2021 | November 30, 2026 | SETIAWAN, VERONICA WENDY | reporter.nih.gov |
| Hereditary Genetics of Hepatocellular Carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $2,655,540 | February 1, 2022 | June 30, 2027 | WANGENSTEEN, KIRK J | reporter.nih.gov |
| Discovery of novel therapeutic targets for NASH through deep phenotyping of human knockouts and mechanistic studies | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,636,860 | September 15, 2022 | June 30, 2026 | TABAS, IRA A | reporter.nih.gov |
| Cutaneous biomarkers of pediatric non-alcoholic fatty liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,615,502 | June 17, 2022 | March 31, 2027 | MOUZAKI, MARIALENA | reporter.nih.gov |
| Regulation of Metabolism by FGF21 | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,614,390 | July 15, 2015 | June 30, 2028 | POTTHOFF, MATTHEW JOSEPH | reporter.nih.gov |
| Systems Genetics Dissection of Non-alcoholic Steatohepatitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,612,818 | July 1, 2019 | March 31, 2028 | LUSIS, ALDONS JAKE | reporter.nih.gov |
| Recruitment for the efficacy trial of Tele-Harm Reduction in a federally qualified health center operated syringe services program | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,609,496 | May 1, 2021 | April 30, 2026 | TOOKES, HANSEL EMORY | reporter.nih.gov |
| Bio-Psycho-Social Drivers of Disparities in Liver Disease Progression among Korean Americans with Hepatitis B Infection | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,557,384 | April 12, 2021 | March 31, 2026 | JUON, HEE-SOON | reporter.nih.gov |
| First-in-human study of a potent anti-HBsAg neutralizing antibody | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,534,231 | March 20, 2023 | February 28, 2027 | CASKEY, MARINA | reporter.nih.gov |
| Tumor-promoting and tumor-suppressive roles of Hepatic Stellate Cell Subpopulations in NASH-HCC | NIH | National Cancer Institute | 2021 to 2025 | $2,533,680 | July 20, 2021 | June 30, 2026 | SCHWABE, ROBERT F. | reporter.nih.gov |
| Leveraging HCV Phylogenetic Networks to Prevent HIV and Other Blood Borne Infections Among People Who Inject Drugs | NIH | National Institute on Drug Abuse | 2021 | $2,520,000 | June 1, 2021 | May 31, 2026 | AKIYAMA, MATTHEW | reporter.nih.gov |
| ANALYSIS OF INTRAHEPATIC MACROPHAGE PROFILES FOR PREDICTING RISK OF FIBROSIS DEVELOPMENT IN PATIENTS WITH DIFFERENT TYPES OF CHRONIC LIVER DISEASE | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,517,485 | April 1, 2021 | March 31, 2027 | STEVENSON, HEATHER L | reporter.nih.gov |
| Role of antibodies in hepatitis E virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,508,951 | April 19, 2023 | March 31, 2028 | FENG, ZONGDI | reporter.nih.gov |
| Understanding human antibody responses to chronic viral hepatitis C | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,488,538 | January 17, 2022 | December 31, 2026 | LAW, MANSUN | reporter.nih.gov |
| Immune correlates of protection against hepacivirus persistence. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,486,556 | April 1, 2021 | September 30, 2025 | KAPOOR, AMIT | reporter.nih.gov |
| TERT mRNA lipid nanoparticles to extend telomeres to treat alcoholic hepatitis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2024 | $2,484,849 | September 10, 2020 | August 31, 2025 | RAMUNAS, JOHN | reporter.nih.gov |
| The role of AEG-1 in NASH and NASH-HCC | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,484,379 | July 25, 2016 | December 31, 2025 | SARKAR, DEVANAND | reporter.nih.gov |
| HBV Capsid Effectors | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,475,992 | June 1, 2017 | February 28, 2027 | SCHINAZI, RAYMOND FELIX | reporter.nih.gov |
| Molecular Magnetic Resonance Imaging of Inflammation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,451,935 | August 1, 2019 | November 30, 2029 | GALE, ERIC MICHAEL | reporter.nih.gov |
| Dissecting the Role of Arachidonic Acid Metabolic Pathways Involved in Resolution Versus Progression of PM-Induced Cardiometabolic Toxicity | NIH | National Institute of Environmental Health Sciences | 2022 to 2025 | $2,445,294 | February 11, 2022 | November 30, 2026 | ARAUJO, JESUS ANTONIO | reporter.nih.gov |
| New generation of long acting nucleos(t)ides and immune stimulant for treatment of chronic hepatitis B | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,444,033 | March 10, 2022 | February 28, 2027 | OSNA, NATALIA ALEKSANDR | reporter.nih.gov |
| Digital, Community-Led, Social Action Initiative to Reduce Opioid Vulnerability and HIV/HCV in Rural Areas of the Midwest and Appalachia | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,437,500 | May 1, 2019 | April 30, 2025 | ALBARRACIN, DOLORES | reporter.nih.gov |
| A binational cohort of the intersection between substance use, HIV, and associated comorbidities among people who inject drugs in San Diego, CA | NIH | National Institute on Drug Abuse | 2025 | $2,437,310 | July 15, 2025 | May 31, 2030 | STRATHDEE, STEFFANIE A. | reporter.nih.gov |
| Integrative Physiology of Thyroid Hormone Receptors and Nuclear Receptor Corepressors | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,435,612 | June 1, 1991 | April 30, 2029 | LAZAR, MITCHELL A. | reporter.nih.gov |
| Continuation of the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Clinical Center-Cleveland site | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,432,868 | June 15, 2002 | June 30, 2027 | DASARATHY, SRINIVASAN | reporter.nih.gov |
| YAP signaling in the pathogenesis of NAFLD in people living with HIV | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,422,019 | September 26, 2023 | July 31, 2028 | CHUNG, RAYMOND T | reporter.nih.gov |
| ATP Binding Cassette Transporters in Health and Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,408,231 | April 9, 2021 | January 31, 2025 | TARLING, ELIZABETH JOANNA | reporter.nih.gov |
| Defining the role of the RNA modification N6-methyladenosine during Flaviviridae virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,403,276 | June 1, 2016 | January 31, 2027 | HORNER, STACY MICHELLE | reporter.nih.gov |
| Development of polymeric synthetic biomaterial IP-001 to potentiate asystemic immunotherapy of hepatocellular carcinoma via thermal ablation | NIH | National Cancer Institute | 2021 to 2024 | $2,400,000 | August 16, 2021 | August 31, 2025 | LAM, SIU KIT | reporter.nih.gov |
| Biomarkers of Alcoholic Hepatitis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $2,386,096 | June 1, 2020 | May 31, 2026 | ARTEEL, GAVIN E | reporter.nih.gov |
| Quantitative MRI and Deep Learning Technologies for Classification of NAFLD | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $2,364,000 | August 1, 2022 | April 30, 2027 | WU, HOLDEN H | reporter.nih.gov |
| Kentucky Outreach Service Kiosk (KyOSK): Reducing Overdose, Hepatitis C, and Other Drug-related Risks in Rural Appalachia through Health Kiosks | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,359,307 | August 15, 2022 | June 30, 2027 | YOUNG, APRIL MARIE | reporter.nih.gov |
| Disparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods Study | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,331,243 | August 1, 2020 | June 30, 2025 | SHAPIRO, MARTIN F. | reporter.nih.gov |
| Heat shock protein 90 in alcoholic liver disease: targeting macrophage Function | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2025 | $2,330,377 | August 1, 2009 | June 30, 2027 | MANDREKAR, PRANOTI | reporter.nih.gov |
| Adipsin in NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,324,625 | July 1, 2022 | April 30, 2027 | PAJVANI, UTPAL | reporter.nih.gov |
| Hepatocyte-derived extracellular vesicles in alcoholic liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $2,324,384 | July 1, 2020 | March 31, 2026 | FELDSTEIN, ARIEL | reporter.nih.gov |
| The role of IL-17 signaling in alcohol-induced HCC | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,322,600 | August 6, 2021 | May 31, 2027 | KISSELEVA, TATIANA | reporter.nih.gov |
| Predicting outcomes in nonalcoholic steatohepatitis with advanced fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,310,512 | September 15, 2022 | June 30, 2027 | SANYAL, ARUN J | reporter.nih.gov |
| A vascularized patient-derived iPSC liver acinus microphysiology system as an innovative precision medicine platform for optimizing clinical trial design for nonalcoholic fatty liver disease | NIH | National Center for Advancing Translational Sciences | 2022 to 2024 | $2,306,928 | July 15, 2020 | June 30, 2026 | TAYLOR, D. LANSING | reporter.nih.gov |
| Small molecule antagonists targeting EphB receptors for the treatment of nonalcoholic steatohepatitis (NASH) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,297,570 | August 1, 2021 | May 31, 2026 | MIMCHE, PATRICE | reporter.nih.gov |
| Integrated analysis of HBV-specific CD4 T cell and B cell responses to define their role in chronic hepatitis B and HBV functional cure. | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,286,418 | July 1, 2024 | May 31, 2029 | LAUER, GEORG MICHAEL | reporter.nih.gov |
| Rip Proteins in Innate Immune Signaling | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,272,136 | December 15, 2008 | August 31, 2025 | KELLIHER, MICHELLE ALICE | reporter.nih.gov |
| Evaluation of a persuasive health communication intervention designed to increase HIV/HCV screening among emergency departments patients who currently, formerly or never injected drugs | NIH | National Institute on Drug Abuse | 2022 to 2024 | $2,264,864 | September 30, 2022 | July 31, 2027 | MERCHANT, ROLAND C | reporter.nih.gov |
| HDAC1 as a nutrient sensor in the development and progression of NAFLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,254,125 | June 3, 2022 | March 31, 2027 | SHI, HANG | reporter.nih.gov |
| Mechanisms of hepatitis B virus cccDNA formation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,246,607 | May 15, 2020 | April 30, 2025 | PLOSS, ALEXANDER | reporter.nih.gov |
| Control of Lipogenesis and Hepatic Steatosis by Caspase-2 | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,246,301 | March 15, 2019 | November 30, 2025 | KARIN, MICHAEL | reporter.nih.gov |
| Fibrogenesis Targeted Manganese Based MRI Contrast Agent | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2024 | $2,239,969 | September 15, 2022 | August 31, 2025 | HOFFMAN, VERA | reporter.nih.gov |
| Integrated Care for Addiction, HIV and HCV Research and Education (ICAHRE) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,234,611 | July 1, 2017 | June 30, 2027 | STEIN, MICHAEL D | reporter.nih.gov |
| Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort) | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,227,803 | April 1, 2019 | March 31, 2026 | CRANE, HEIDI M. | reporter.nih.gov |
| New insights into the functional diversity of the hepatic antiviral T cell response during hepacivirus infection in vivo | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,227,294 | June 1, 2022 | May 31, 2027 | BILLERBECK, EVA | reporter.nih.gov |
| Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,223,594 | August 20, 2021 | June 30, 2027 | REMISZEWSKI, STACY | reporter.nih.gov |
| Novel mechanism based treatment to improve tissue injury in alcoholic hepatitis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $2,223,387 | September 25, 2020 | July 31, 2025 | DASARATHY, SRINIVASAN | reporter.nih.gov |
| Southern Liver Health Cohort | NIH | National Cancer Institute | 2021 to 2022 | $2,219,249 | September 21, 2021 | August 31, 2023 | HOYO, CATHRINE | reporter.nih.gov |
| Understanding the metabolic pathology of pediatric obesity and NAFLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,218,267 | April 22, 2022 | January 31, 2027 | SHORT, KEVIN R. | reporter.nih.gov |
| Mechanistic function of HCV NS5A targeted by the potent inhibitors | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,218,100 | February 1, 2020 | January 31, 2026 | YI, MINKYUNG | reporter.nih.gov |
| Mechanisms of Hepadnavirus Assembly and Replication | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,212,330 | February 15, 1999 | August 31, 2028 | HU, JIANMING | reporter.nih.gov |
| Systemic immunoregulatory consequences of bacterial translocation during health and disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,209,196 | September 21, 2021 | June 30, 2026 | MEISEL, MARLIES | reporter.nih.gov |
| Etiology of Persistent Microalbuminuria in Nigeria | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,202,068 | July 1, 2021 | May 31, 2026 | WESTER, C. WILLIAM | reporter.nih.gov |
| Ex-vivo bioengineered technology to unravel dysfunction due to non-alcoholic steatohepatitis (NASH) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,201,102 | July 1, 2023 | April 30, 2027 | WERTHEIM, JASON A | reporter.nih.gov |
| Estimating the population size of persons who inject drugs in New York | NIH | National Institute on Drug Abuse | 2021 to 2022 | $2,200,197 | June 1, 2021 | December 13, 2022 | BRADLEY, HEATHER | reporter.nih.gov |
| Role of heat shock transcription factor HSF1 in tumorigenesis | NIH | National Cancer Institute | 2021 to 2025 | $2,193,704 | July 1, 1996 | January 31, 2027 | MIVECHI, NAHID F | reporter.nih.gov |
| Insulin Regulation of Hepatic Function via Zone-Specific Transcriptional Programs | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,193,363 | May 1, 2021 | April 30, 2027 | BIDDINGER, SUDHA B | reporter.nih.gov |
| HBV-specific T cell immunity in HBV/HIV coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,189,677 | August 1, 2025 | July 31, 2028 | VINIKOOR, MICHAEL JEFFREY | reporter.nih.gov |
| RECK regulation of NASH and fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,185,559 | May 15, 2022 | April 30, 2027 | RECTOR, RANDY SCOTT | reporter.nih.gov |
| Lipotoxicity and Liver Inflammation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,182,776 | April 15, 2020 | February 29, 2028 | IBRAHIM, SAMAR | reporter.nih.gov |
| Therapeutic Mitochondrial Uncouplers | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,181,641 | May 1, 2021 | December 31, 2025 | SANTOS, WEBSTER L | reporter.nih.gov |
| Understanding the Multilevel Drivers of Liver Cancer Disparities | NIH | National Cancer Institute | 2021 to 2023 | $2,174,412 | August 16, 2019 | July 31, 2025 | SHARIFF-MARCO, SALMA | reporter.nih.gov |
| Integrative Liver Cell Core | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,169,055 | June 15, 2001 | May 31, 2027 | TSUKAMOTO, HIDEKAZU | reporter.nih.gov |
| Impaired VLDL secretion in progression of NAFLD and NASH in mice and humans | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,167,149 | July 16, 2019 | June 30, 2028 | DAVIDSON, NICHOLAS O. | reporter.nih.gov |
| Exosomal biomarkers for the early detection of hepatocellular carcinoma | NIH | National Cancer Institute | 2023 to 2025 | $2,166,339 | August 8, 2023 | July 31, 2028 | GOEL, AJAY | reporter.nih.gov |
| Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $2,139,998 | September 11, 2017 | August 31, 2024 | BLITZER, JEREMY | reporter.nih.gov |
| The Saint Louis University Component of the NASH Clinical Research Network | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,135,402 | May 20, 2002 | June 30, 2027 | NEUSCHWANDER-TETRI, BRENT A | reporter.nih.gov |
| Mechanisms of microcystin-induced hepatocellular carcinoma in nonalcoholic steatohepatitis | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $2,132,242 | January 19, 2021 | October 31, 2026 | CLARKE, JOHN DANIEL | reporter.nih.gov |
| A Role for the Novel HAF-NFkappaB Axis in Driving Obesity-Associated Liver Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,131,677 | September 1, 2025 | August 31, 2027 | KOH, MEI YEE | reporter.nih.gov |
| Ketone Body Metabolism and Integrated Metabolic Homeostasis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,128,893 | August 5, 2011 | June 30, 2025 | CRAWFORD, PETER A | reporter.nih.gov |
| A novel approach to treat non-alcoholic steatohepatitis (NASH) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $2,122,291 | June 1, 2021 | July 31, 2024 | ARBEENY, CYNTHIA | reporter.nih.gov |
| Toxic lipid intermediate accumulation and cobalamin depletion promote AHR-mediated hepatotoxicity and the progression of non-alcoholic fatty liver disease (NAFLD)-like pathologies | NIH | National Institute of Environmental Health Sciences | 2022 to 2025 | $2,117,038 | September 1, 2025 | August 31, 2027 | ZACHAREWSKI, TIMOTHY R. | reporter.nih.gov |
| Epidemiology of diet, metabolism and non-alcoholic fatty liver disease in Hispanic/Latino adults | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,113,449 | September 15, 2023 | July 31, 2027 | KAPLAN, ROBERT C | reporter.nih.gov |
| Microbiome and Intestinal Innate Immune Response in Alcoholic Liver Disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,112,911 | September 25, 2011 | June 30, 2026 | SCHNABL, BERND G. | reporter.nih.gov |
| Structural characterization of native HBV capsids and virions from human cells | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,112,197 | June 14, 2023 | May 31, 2028 | WANG, JOSEPH CHE-YEN | reporter.nih.gov |
| Assessing performance of a Hepatitis C Emergency Department (HepC-END) Screening Tool | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,102,922 | September 15, 2023 | July 31, 2028 | PARK, HAESUK | reporter.nih.gov |
| Mechanisms underlying hepatic immune cell recruitment in nonalcoholic fatty liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,092,488 | April 1, 2021 | March 31, 2027 | RAEMAN, REBEN | reporter.nih.gov |
| TNF alpha and Recovery from Alcoholic Liver Injury | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,088,463 | May 5, 2025 | April 30, 2030 | DIEHL, ANNA MAE ELIZABETH | reporter.nih.gov |
| Pathobiology of Liver Injury | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,077,361 | September 23, 2016 | August 31, 2026 | MALHI, HARMEET | reporter.nih.gov |
| Responding to the Increase in Substance Use, HIV, HCV, and Overdose in New England (RISE-NE) | NIH | National Institute on Drug Abuse | 2025 | $2,076,525 | August 15, 2025 | May 31, 2030 | BAZZI, ANGELA ROBERTSON | reporter.nih.gov |
| Cholesterol toxicity in alcohol-associated hepatitis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2025 | $2,069,392 | May 15, 2023 | April 30, 2028 | JIANG, ZHENGHUI GORDON | reporter.nih.gov |
| Role of alcohol adapted Kupffer cells in the progression and resolution of ALD | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,068,172 | September 27, 2000 | February 29, 2028 | WEINMAN, STEVEN A | reporter.nih.gov |
| Synergistic effects of ECM and heterotypic crosstalk on cellular responses in non-alcoholic fatty liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,068,034 | February 8, 2018 | June 30, 2027 | KHETANI, SALMAN R | reporter.nih.gov |
| A novel cholinergic circuitry in alcoholic liver disease (NIAAA) | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,066,485 | March 15, 2021 | January 31, 2027 | WU, JUN | reporter.nih.gov |
| Critical Lipid Species in the Hepatovirus Lifecycle | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,065,233 | December 12, 2019 | May 31, 2025 | LEMON, STANLEY M. | reporter.nih.gov |
| Epitope-Based CSP Vaccines Optimized to Achieve Long-Term Sterile Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,065,107 | August 23, 2023 | July 31, 2027 | MILICH, DAVID R. | reporter.nih.gov |
| A novel pathway controls liver injury in NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,058,572 | June 23, 2022 | March 31, 2027 | ZHAO, PENG | reporter.nih.gov |
| Nonalcoholic Fatty Liver Disease (NAFLD) in Polycystic Ovary Syndrome: The Role of Androgens on Liver Injury and NAFLD Progression | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,051,810 | September 1, 2023 | June 30, 2028 | SARKAR, MONIKA | reporter.nih.gov |
| Genetic Viral and Host Adaptations to Breach Species Barriers of HCV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,049,912 | July 1, 2013 | December 31, 2028 | PLOSS, ALEXANDER | reporter.nih.gov |
| Elimination of HCV and related liver disease among HIV-infected and -uninfected people who inject drugs | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,039,441 | January 15, 2019 | December 31, 2025 | THOMAS, DAVID L | reporter.nih.gov |
| Evaluating risk factors for cirrhosis progression and response to statin therapy among a cohort of patients with cirrhosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,035,766 | September 22, 2021 | July 31, 2027 | GOLDBERG, DAVID SETH | reporter.nih.gov |
| Optimizing SWELL1 modulators to treat non-alcoholic steatohepatitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $2,035,065 | September 16, 2020 | August 31, 2025 | LERNER, DANIEL J | reporter.nih.gov |
| Hepatic TGFbeta1 in Control of Type 2 Diabetes and NASH via FoxO1 Signaling | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,019,371 | December 1, 2021 | November 30, 2026 | GUO, SHAODONG | reporter.nih.gov |
| Development of caspase-6 inhibitors for treatment of NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,016,023 | January 1, 2023 | November 30, 2027 | SALTIEL, ALAN R. | reporter.nih.gov |
| Candidate selection of a LPAR1 antagonist for therapeutic application in NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2024 | $2,013,280 | September 20, 2021 | June 30, 2026 | TUCCI, FABIO COHEN | reporter.nih.gov |
| Microchip for HBV testing using HIV-infected blood samples | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,012,162 | February 6, 2023 | November 30, 2024 | SHAFIEE, HADI | reporter.nih.gov |
| Mechanisms of insulin resistance related to nonalcoholic steatohepatitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $2,007,393 | March 9, 2015 | March 31, 2025 | CZECH, MICHAEL P | reporter.nih.gov |
| Estimating the cost of peer specialists providing comprehensive healthcare services at a syringe services program | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,007,015 | June 1, 2023 | March 31, 2028 | TOOKES, HANSEL EMORY | reporter.nih.gov |
| Role of SMPDL3B in obesity-associated non-alcoholic fatty liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,006,588 | July 1, 2022 | April 30, 2027 | WANG, SHUXIA | reporter.nih.gov |
| Imaging Hepatic Energy Metabolism in NAFLD/NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,004,135 | April 1, 2022 | December 31, 2026 | MERRITT, MATTHEW E | reporter.nih.gov |
| Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin | NIH | National Cancer Institute | 2022 to 2023 | $2,000,000 | April 6, 2020 | July 31, 2025 | SHAFIRSTEIN, GAL | reporter.nih.gov |
| Rapid point-of-care molecular test for HCV VL | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,996,224 | September 1, 2021 | March 31, 2027 | FISHER, JAY KENNETH | reporter.nih.gov |
| Leveraging the plasma virome as a biological indicator of HIV risk and transmission networks among people who inject drugs | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,994,072 | June 1, 2023 | March 31, 2028 | KANDATHIL, ABRAHAM | reporter.nih.gov |
| Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,986,219 | January 20, 2019 | December 31, 2025 | MCCLAIN, DONALD A. | reporter.nih.gov |
| Developing and Automating an Extracellular Vesicle-Based Test for Early Detection of Hepatocellular Carcinoma | NIH | National Cancer Institute | 2023 to 2025 | $1,984,827 | September 14, 2023 | August 31, 2026 | TSENG, HSIAN-RONG | reporter.nih.gov |
| Adoptive MHC-E-Restricted T Cell Therapy for the Treatment of Chronic Hepatitis B Virus Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,982,398 | June 1, 2019 | May 31, 2024 | BURWITZ, BENJAMIN J | reporter.nih.gov |
| Understanding and Improving the Effectiveness of Public Health Laboratory Networks for Infectious Diseases in Ghana | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,975,313 | March 11, 2019 | February 28, 2025 | SCHROEDER, LEE FREDERICK | reporter.nih.gov |
| A renewable and genetically tractable human stem cell-derived multicellular platform for the study of fibrotic liver diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,974,527 | March 1, 2021 | February 28, 2025 | RICE, CHARLES M | reporter.nih.gov |
| Peer-based Retention of people who Use Drugs in Rural Research (PROUD-R2) | NIH | National Center for Advancing Translational Sciences | 2021 to 2023 | $1,971,059 | September 18, 2018 | July 31, 2024 | KORTHUIS, PHILIP TODD | reporter.nih.gov |
| Human mechanisms of virus persistence in an AAV-based mouse model of chronic HBV infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,966,264 | May 6, 2020 | April 30, 2026 | ROBEK, MICHAEL | reporter.nih.gov |
| Click Chemistry-Mediated Surface Protein Assay for Quantifying Subpopulations of Hepatocellular Carcinoma-associated Extracellular Vesicles | NIH | National Cancer Institute | 2023 to 2025 | $1,964,033 | July 1, 2023 | June 30, 2028 | ZHU, YAZHEN | reporter.nih.gov |
| Mass spectrometry for highly sensitive and sample-sparing analysis of extracellular vesicles in liver diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,963,066 | August 1, 2023 | May 31, 2027 | REVZIN, ALEXANDER | reporter.nih.gov |
| Hepatic stellate cells in NASH fibrosis and HCC | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,960,030 | April 1, 2021 | March 31, 2025 | FRIEDMAN, SCOTT L. | reporter.nih.gov |
| A Precision Medicine for Alcohol-Associated Liver Disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2024 | $1,959,401 | September 20, 2023 | August 31, 2025 | LIU, WANQING | reporter.nih.gov |
| San Diego Cirrhosis Clinical Research Network | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,949,305 | September 9, 2021 | July 31, 2027 | LOOMBA, ROHIT | reporter.nih.gov |
| Molecular Mechanisms of HBV cccDNA Formation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,933,309 | March 11, 2016 | June 30, 2027 | GUO, HAITAO | reporter.nih.gov |
| Developing a renewable and dissectible human liver for the study of HBV/HCV infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,932,000 | August 18, 2022 | July 31, 2027 | WU, XIANFANG | reporter.nih.gov |
| LXR-Dependent Cholesterol Sensing | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,928,942 | April 1, 2022 | June 30, 2026 | SCHULMAN, IRA G | reporter.nih.gov |
| Maternal effect on offspring immunity against hepatitis B virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,925,049 | July 3, 2019 | June 30, 2025 | OU, J.-H. JAMES | reporter.nih.gov |
| Sphingosine kinase 2 in sexual dimorphism of hepatocellular carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $1,923,553 | September 1, 2022 | August 31, 2027 | GREEN, CHRISTOPHER D | reporter.nih.gov |
| Dissecting the NRG4 hormonal checkpoint in metabolic liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,912,088 | July 15, 2015 | June 30, 2025 | LIN, JIANDIE D | reporter.nih.gov |
| Inhibition of EGF Receptor Prevents and Reverses Non-Alcoholic Fatty Liver Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,893,133 | February 3, 2021 | January 31, 2026 | MICHALOPOULOS, GEORGE K | reporter.nih.gov |
| The UW Medical Student Addiction Research (MedStAR) Program to Address Substance Use and Disorders in Urban and Rural Communities in Five Western States | NIH | National Institute on Drug Abuse | 2021 to 2025 | $1,882,544 | May 1, 2020 | April 30, 2030 | TSUI, JUDITH | reporter.nih.gov |
| Role of HCV exosomes in intercellular communication | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,877,240 | April 15, 2020 | February 28, 2026 | HAHN, YOUNG S. | reporter.nih.gov |
| Modeling Viral and T Lymphocyte Dynamics | NIH | Office of the Director, National Institutes of Health | 2021 to 2024 | $1,866,528 | December 23, 2019 | November 30, 2025 | PERELSON, ALAN S | reporter.nih.gov |
| Mechanisms of HBV Functional Cure During Tenofovir-based ART in HIV/HBV Coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,857,031 | September 1, 2019 | August 31, 2025 | VINIKOOR, MICHAEL JEFFREY | reporter.nih.gov |
| Pre-clinical Validation of A Novel Protein Drug Candidate for ASH and NASH Treatment | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,843,194 | September 1, 2021 | June 30, 2025 | YANG, JENNY J. | reporter.nih.gov |
| Ending transmission of HIV, HCV, and STDs and overdose in rural communities of people who inject drugs (ETHIC) | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,836,801 | August 15, 2017 | July 31, 2023 | PHO, MAI TUYET | reporter.nih.gov |
| Testing of Drug Combinations For Mycobacterium tuberculosis (MTB) in Mice | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,831,148 | September 1, 2022 | November 30, 2025 | SLAYDEN, RICHARD | reporter.nih.gov |
| Novel pathways in the pathogenesis and pathophysiology of NAFLD in Hispanics | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2023 | $1,820,623 | March 12, 2019 | November 30, 2024 | NAJJAR, SONIA M. | reporter.nih.gov |
| IRAKM and MINCLE in ALD | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2025 | $1,806,489 | August 17, 2023 | July 31, 2028 | NAGY, LAURA E. | reporter.nih.gov |
| Harnessing the power of peer navigation and mHealth to reduce health disparities in Appalachia | NIH | National Institute of Nursing Research | 2021 to 2024 | $1,805,022 | August 27, 2020 | March 21, 2025 | RHODES, SCOTT D | reporter.nih.gov |
| Rapid, Point-of-Care Diagnostics for Hepatitis C Virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,799,981 | August 12, 2022 | August 12, 2025 | UNGEWITTER, ERICA | reporter.nih.gov |
| The pathophysiological function of PNPLA3-148M variant in alcohol-induced liver injury | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2025 | $1,799,014 | May 1, 2022 | March 31, 2027 | DONG, X. CHARLIE | reporter.nih.gov |
| USC Cirrhosis Clinical Center | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,796,054 | September 22, 2021 | July 31, 2027 | TERRAULT, NORAH A. | reporter.nih.gov |
| Evaluation of anti-fibrotic and anti-inflammatory semi-synthetic oxysterol, Oxy210, as a therapeutic drug candidate for non-alcoholic steatohepatitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2024 | $1,786,691 | May 1, 2023 | April 30, 2026 | PARHAMI, FARHAD | reporter.nih.gov |
| Non-immunosuppressive Sanglifehrin Analogs as Therapeutic Agents for Viral Hepatitis-induced Liver Damage Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,783,750 | April 1, 2020 | March 31, 2026 | GALLAY, PHILIPPE ANDRE | reporter.nih.gov |
| In search of an HBV cure: novel model systems and targets | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,782,852 | June 10, 2019 | May 31, 2024 | RICE, CHARLES M | reporter.nih.gov |
| AlcHepNet DCC UMMS | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2023 | $1,781,820 | August 1, 2018 | June 30, 2024 | BARTON, BRUCE A | reporter.nih.gov |
| UC San Diego Raising Advancement and Parity for Infectious Disease Researchers (RAPID) Faculty Development Program | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,778,757 | August 10, 2020 | July 31, 2030 | TREJO, JOANN | reporter.nih.gov |
| Comprehensive noninvasive assessment of liver histopathology in nonalcoholic fatty liver disease (NAFLD) via magnetic resonance imaging, cytometry and elastography (MR-ICE) | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2025 | $1,774,440 | May 1, 2014 | November 30, 2026 | YIN, MENG | reporter.nih.gov |
| Transcriptional and non-transcriptional function of IRF3 in ALD | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $1,763,975 | July 5, 2019 | June 30, 2029 | NAGY, LAURA E. | reporter.nih.gov |
| Mediators of fatty liver disease during HIV/SIV and cART treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,758,840 | February 19, 2018 | January 31, 2024 | SODORA, DONALD L | reporter.nih.gov |
| Notch, Type 2 Diabetes and NAFLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,752,429 | July 1, 2015 | March 31, 2024 | PAJVANI, UTPAL | reporter.nih.gov |
| Pathobiology of Nonalcoholic Steatohepatitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,735,008 | September 30, 2021 | July 31, 2026 | HIRSOVA, PETRA | reporter.nih.gov |
| 1/4-American Consortium of Early Liver Transplantation-Prospective Alcohol-associated liver disease Cohort Evaluation (ACCELERATE-PACE) | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2025 | $1,732,406 | August 1, 2023 | July 31, 2030 | TERRAULT, NORAH A. | reporter.nih.gov |
| Integrated therapies for alcohol use and ALD (ITAALD) Network - IU Clinical Center | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $1,707,981 | September 15, 2012 | June 30, 2029 | CHALASANI, NAGA P | reporter.nih.gov |
| A new humanized mouse model to study HBV gene editing | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,705,880 | August 1, 2024 | July 31, 2029 | JEROME, KEITH R | reporter.nih.gov |
| PPARgamma-regulated mechanisms in hepatocytes that promote NAFLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,702,743 | February 1, 2022 | January 31, 2027 | CORDOBA-CHACON, JOSE | reporter.nih.gov |
| Hepatic TrkB-T1 signaling in NASH pathogenesis and resolution | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,695,001 | April 1, 2023 | January 31, 2027 | LIN, JIANDIE D | reporter.nih.gov |
| Hepatic mTORC1 Signaling and the Regulation of Lipid Homeostasis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,694,012 | March 1, 2021 | January 31, 2025 | TITCHENELL, PAUL MICHAEL | reporter.nih.gov |
| A Precision Targeted Therapeutics for Nonalcoholic Fatty Liver Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,693,379 | July 1, 2021 | April 30, 2026 | LIU, WANQING | reporter.nih.gov |
| Role of Screening and Early Intervention in Primary Care with Low-Dose Pioglitazone for Patients with T2DM and NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,689,302 | May 8, 2020 | February 28, 2026 | CUSI, KENNETH | reporter.nih.gov |
| Matrix in pre-cirrhotic HCC | NIH | National Cancer Institute | 2023 to 2025 | $1,687,806 | March 15, 2023 | February 29, 2028 | TOROK, NATALIE J. | reporter.nih.gov |
| Role of Soluble Epoxide Hydrolase in Alcohol-Associated Liver Disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2025 | $1,662,196 | June 1, 2022 | March 31, 2027 | KIRPICH, IRINA A. | reporter.nih.gov |
| Role of SAMe in the Progression of Nonalcoholic Fatty Liver Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,656,555 | September 20, 2002 | June 30, 2026 | LU, SHELLY CHI-LOO | reporter.nih.gov |
| Development of standardized immunoassays and virus panels for HCV vaccine research | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,651,974 | July 23, 2021 | June 30, 2025 | BAILEY, JUSTIN RICHARD | reporter.nih.gov |
| Role of Base Excision Repair in Limiting Hepatocellular Carcinomas | NIH | National Institute of Environmental Health Sciences | 2021 to 2024 | $1,650,684 | January 1, 2020 | October 31, 2024 | LLOYD, R. STEPHEN | reporter.nih.gov |
| Autophagy and the Replication of Hepatitis B Virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,650,000 | February 3, 2020 | January 31, 2026 | OU, J.-H. JAMES | reporter.nih.gov |
| Role of Beta Spectrin and Smad in Alcohol-Induced Liver and GI Cell Proliferation | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $1,640,516 | August 20, 2024 | July 31, 2029 | MISHRA, LOPA | reporter.nih.gov |
| Highly penetrant and immunogenic mouse models of non-viral HCC that are suitable for evaluation of immune checkpoint inhibitors | NIH | National Cancer Institute | 2021 to 2023 | $1,637,378 | December 1, 2018 | November 30, 2024 | KARIN, MICHAEL | reporter.nih.gov |
| Sulfur Amino Acid Metabolism and Regulation of Hepatic Metabolic Flexibility | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,632,006 | January 1, 2022 | December 31, 2025 | LI, TIANGANG | reporter.nih.gov |
| Disturbed Crosstalk between Cholesterol Homeostasis and Inflammation Resolution in NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,626,085 | May 1, 2023 | August 10, 2025 | CAI, BISHUANG | reporter.nih.gov |
| Lipidated Amino Acids in Cardiometabolic Diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,621,509 | June 2, 2022 | March 31, 2027 | ROM, OREN | reporter.nih.gov |
| Developing Woodchucks Susceptible to Hepatitis B Virus Infection by Modifying the Virus or Host | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,621,356 | July 17, 2024 | June 30, 2029 | MENNE, STEPHAN | reporter.nih.gov |
| Glycopathology of HCC: identification of the source cells of serum fucosylation | NIH | National Cancer Institute | 2021 to 2023 | $1,620,312 | March 14, 2019 | February 28, 2025 | MEHTA, ANAND S. | reporter.nih.gov |
| Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $1,615,258 | May 15, 2018 | April 30, 2025 | STANLEY, TAKARA LEAH | reporter.nih.gov |
| Alcohol-induced hepatotoxicity - implications of secretin/secretin receptor axis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2023 | $1,614,707 | September 5, 2020 | September 11, 2023 | ALPINI, GIANFRANCO D | reporter.nih.gov |
| Next generation quantitative HCV drug resistance assay | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $1,611,097 | March 1, 2018 | June 30, 2025 | WAGNER, RICHARD | reporter.nih.gov |
| Hepatic insulin resistance integrates T2D and NAFLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,593,841 | September 5, 2024 | July 31, 2028 | WHITE, MORRIS F. | reporter.nih.gov |
| Animal Model to study heterogeneous outcomes of HCV Infection and Pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,575,922 | June 1, 2024 | April 30, 2029 | KAPOOR, AMIT | reporter.nih.gov |
| Collaborative Justice-Involved Research and Training Program on Substance Use and HIV at Brown University Health | NIH | National Institute on Drug Abuse | 2021 to 2025 | $1,575,185 | June 1, 2014 | December 31, 2029 | BECKWITH, CURT G | reporter.nih.gov |
| Development of Controlled Release Mitochondrial Protonophore (CRMP) as a Novel Treatment for Type-2 Diabetes and Non-Alcoholic Steatohepatitis in Dysmetabolic Non-Human Primates | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,574,788 | March 15, 2019 | February 28, 2025 | SHULMAN, GERALD I | reporter.nih.gov |
| Altering Hepatitis B Virus assembly through pharmacological intervention | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,572,240 | May 6, 2020 | April 30, 2026 | GUMBART, JAMES C. | reporter.nih.gov |
| Breaching the species barrier: Towards an immunocompetent HBV-susceptible mouse model | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,568,998 | June 12, 2024 | May 31, 2029 | RICE, CHARLES M | reporter.nih.gov |
| Dissecting Hepatitis B Vaccine Adjuvant Effects on Immune Responses and the HIV Reservoir in PLWH | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,567,217 | July 25, 2024 | May 31, 2029 | COX, ANDREA L | reporter.nih.gov |
| Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,566,354 | September 24, 2018 | August 31, 2024 | SU, LISHAN | reporter.nih.gov |
| Long-acting Antiviral Treatment for HBV | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,562,010 | July 10, 2024 | June 30, 2029 | HO, RODNEY J.Y. | reporter.nih.gov |
| Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD)- Cleveland Clinic Clinical Center | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $1,561,055 | August 1, 2018 | June 30, 2029 | DASARATHY, SRINIVASAN | reporter.nih.gov |
| Intestine FXR activation by LGG-derived nanoparticles in alcohol-associated liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2025 | $1,559,904 | August 15, 2022 | May 31, 2027 | FENG, WENKE | reporter.nih.gov |
| Mechanism for hepatitis E virus exit from polarized hepatocytes | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,554,075 | March 14, 2023 | February 29, 2028 | FENG, ZONGDI | reporter.nih.gov |
| Novel therapeutic approach for NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,553,952 | June 4, 2020 | May 31, 2025 | MAITRA, RANGAN | reporter.nih.gov |
| Changes in Bone Quality, Sarcopenia and Fat Distribution in HIV/HCV Patients after HCV Therapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,553,826 | December 1, 2017 | November 30, 2024 | LO RE, VINCENT | reporter.nih.gov |
| Epigenetic Regulation of HBV cccDNA Transcription | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,551,736 | June 16, 2020 | May 31, 2026 | GUO, HAITAO | reporter.nih.gov |
| ANTIVIRAL DRUGS TO CURE CHRONIC HEPATITIS B VIRUS INFECTION | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $1,549,999 | April 3, 2023 | August 25, 2025 | ZHANG, YANG-YUAN | reporter.nih.gov |
| HBV cccDNA transcriptional silencing with and without HIV | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,548,735 | July 22, 2024 | May 31, 2029 | BALAGOPAL, ASHWIN | reporter.nih.gov |
| Linking fat metabolism to hepatic fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,547,010 | April 1, 2020 | March 31, 2024 | NAJJAR, SONIA M. | reporter.nih.gov |
| NASH-associated macrophages: regulation and role in disease pathogenesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,545,379 | April 1, 2023 | January 31, 2027 | LIN, JIANDIE D | reporter.nih.gov |
| Protective role of OPN-High macrophages in NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,545,316 | August 5, 2023 | May 31, 2027 | NIETO, NATALIA | reporter.nih.gov |
| Determining hepatocyte-specific mechanisms by which Ube4A regulates NAFLD/NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,543,965 | March 15, 2023 | March 9, 2025 | CHAKRABORTY, ANUTOSH | reporter.nih.gov |
| Axin Stabilization by Novel Small Molecules to Treat Non-alcoholic Steatohepatitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,541,402 | April 1, 2023 | January 31, 2028 | SHU, YAN | reporter.nih.gov |
| Roles of peroxisomal dysfunction in alcohol-related liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2025 | $1,538,891 | June 1, 2023 | February 29, 2028 | ZHONG, WEI | reporter.nih.gov |
| Influence of integrant-derived HBV RNAs encoding the envelope proteins on HBV life cycle | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,537,333 | February 4, 2022 | January 31, 2027 | GUDIMA, SEVERIN O | reporter.nih.gov |
| Reducing Vertical Transmission of Hepatitis B in Africa (REVERT-B Trial) | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $1,534,174 | May 18, 2020 | March 31, 2026 | DIONNE, JODIE ANN | reporter.nih.gov |
| Engaging People Who Use Drugs in Harm Reduction Service Delivery: An Intravention to Reduce Risk of HIV, HCV, Overdose, and Injection-related Infections in Rural Appalachia | NIH | National Institute on Drug Abuse | 2024 | $1,533,697 | September 30, 2024 | August 31, 2026 | YOUNG, APRIL MARIE | reporter.nih.gov |
| The Epidemiology of the Weiss Cohort Project | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,531,257 | August 15, 2020 | June 30, 2023 | WEISS, STANLEY H | reporter.nih.gov |
| Point-of-care Nucleic Acid Amplification Test for pangenomic Hepatitis C diagnosis in outpatient clinics | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,528,985 | July 3, 2024 | May 31, 2029 | POSNER, JONATHAN D | reporter.nih.gov |
| O-glycoproteins in the progression of liver disease | NIH | National Cancer Institute | 2021 to 2023 | $1,525,161 | July 1, 2019 | June 30, 2024 | GOLDMAN, RADOSLAV | reporter.nih.gov |
| Molecular mechanisms of nucleic acid machines | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,520,008 | June 1, 2020 | May 31, 2026 | ENEMARK, ERIC | reporter.nih.gov |
| Perfluoroalkyl Substances (PFASs) and Liver Cancer Risk in the United States | NIH | National Cancer Institute | 2022 to 2023 | $1,519,485 | July 1, 2022 | February 29, 2024 | ZHANG, XUEHONG | reporter.nih.gov |
| Cellular interactions between TGF-beta pathway members and epigenetic regulators in liver and gastrointestinal cancers | NIH | National Cancer Institute | 2021 to 2025 | $1,518,039 | July 18, 2018 | March 31, 2029 | MISHRA, LOPA | reporter.nih.gov |
| Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD) - Virginia Commonwealth University | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $1,515,775 | August 1, 2018 | June 30, 2029 | ARAB, JUAN PABLO | reporter.nih.gov |
| The Role of ERRa in liver lipid dysfunction and pathology | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,515,199 | December 1, 2021 | November 30, 2026 | STILES, BANGYAN | reporter.nih.gov |
| HBV RNaseH inhibitors: Effects on HBV biology and resistance development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,515,000 | December 2, 2019 | November 30, 2025 | TAVIS, JOHN E | reporter.nih.gov |
| A hepatocyte-specific R-spondin mimetic bispecific fusion protein to stimulate hepatocyte regeneration in patients with acute alcoholic hepatitis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2023 | $1,512,500 | September 25, 2020 | June 3, 2024 | TIBBITTS, JAY | reporter.nih.gov |
| Building on Needle Exchange to Optimize HIV Prevention/Treatment | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,506,924 | September 15, 2017 | March 31, 2025 | LUCAS, GREGORY M | reporter.nih.gov |
| Alcohol and Monocyte Signaling Administrative Supplement | NIH | National Institute on Alcohol Abuse and Alcoholism | 2024 to 2025 | $1,506,751 | April 1, 1998 | March 31, 2029 | SZABO, GYONGYI | reporter.nih.gov |
| SBIR PHASE II Point-of-Care HCV Detection | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $1,500,000 | September 15, 2023 | September 14, 2026 | QI, HONG | reporter.nih.gov |
| Development of a hamster model for hepatitis B virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,485,242 | August 9, 2024 | July 31, 2029 | WANG, ZHONGDE | reporter.nih.gov |
| Hepatitis B virus e antigen in viral persistence | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,485,000 | February 20, 2017 | January 31, 2028 | OU, J.-H. JAMES | reporter.nih.gov |
| Multimode Observation of Virus Capsid Assembly | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,480,293 | March 14, 2016 | July 31, 2027 | ZLOTNICK, ADAM | reporter.nih.gov |
| The Epidemiology of the Weiss Cohort Project | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,471,222 | August 15, 2020 | June 30, 2027 | WEISS, STANLEY H | reporter.nih.gov |
| Integrated therapies for alcohol use and ALD (ITAALD) Network – UTSW Clinical Center | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $1,469,096 | August 1, 2018 | June 30, 2029 | MITCHELL, MACK CLARENCE | reporter.nih.gov |
| Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD) – Mayo Clinic | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $1,459,312 | August 1, 2018 | June 30, 2029 | SHAH, VIJAY H. | reporter.nih.gov |
| Mechanisms linking the Branched-Chain alpha-Keto Acid regulatory network to the pathogenesis of NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,457,604 | April 15, 2023 | January 31, 2028 | WHITE, PHILLIP J | reporter.nih.gov |
| Exploiting Natural Killer cells in HIV/HBV co-infection to achieve eradication | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,455,547 | July 9, 2020 | June 30, 2026 | PEPPA, DIMITRA | reporter.nih.gov |
| Identification of the Exposome in Fatty Liver Disease in Mexican American Families Using Genetic Correction | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2022 | $1,454,720 | April 27, 2018 | November 30, 2024 | BLANGERO, JOHN | reporter.nih.gov |
| Immunosuppressive mechanisms responsible for development of non-viral liver cancer and control of its response to immune checkpoint inhibitors | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2022 | $1,450,638 | September 25, 2018 | August 31, 2024 | KARIN, MICHAEL | reporter.nih.gov |
| Clinical Research Network in Nonalcoholic Steatohepatitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,447,477 | July 1, 2002 | June 30, 2027 | KOWDLEY, KRIS | reporter.nih.gov |
| Renal Disposition in NASH | NIH | National Institute of Environmental Health Sciences | 2021 to 2023 | $1,446,306 | February 1, 2019 | January 31, 2025 | CHERRINGTON, NATHAN J | reporter.nih.gov |
| Pharmacologic targeting of the UPR in obesity-linked liver dysfunction | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,443,302 | January 15, 2024 | November 30, 2027 | SAEZ, ENRIQUE | reporter.nih.gov |
| Oregon HIV/Hepatitis and Opioid Prevention and Engagement (OR-HOPE) Study Cost Extension | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,441,353 | August 15, 2017 | July 31, 2023 | KORTHUIS, PHILIP TODD | reporter.nih.gov |
| Universal HCV screening in pregnancy: Examining testing uptake and HCV care | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,439,607 | September 30, 2024 | July 31, 2029 | KAPADIA, SHASHI | reporter.nih.gov |
| Liver lobule zonation, hepatocellular carcinoma (HCC) and β-catenin mediated hepatitis B virus (HBV) biosynthesis | NIH | National Cancer Institute | 2021 to 2024 | $1,430,166 | December 1, 2019 | November 30, 2025 | MCLACHLAN, ALAN | reporter.nih.gov |
| Perfluoroalkyl Substances (PFASs) and Liver Cancer Risk in the United States | NIH | National Cancer Institute | 2024 to 2025 | $1,426,107 | July 1, 2022 | June 30, 2027 | ZHANG, XUEHONG | reporter.nih.gov |
| Role of Interferon-Gamma / Interleukin-12 Axis in Metabolic Liver Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,424,427 | July 1, 2023 | April 30, 2027 | KIM, JASON K | reporter.nih.gov |
| Predict, Detect, Diagnose: Confronting Outbreaks of HIV and Other Infectious Diseases Among People Who Use Drugs | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,422,136 | September 1, 2024 | May 31, 2029 | GONSALVES, GREGG STEVEN | reporter.nih.gov |
| Estimating the population size of persons who inject drugs in New York | NIH | National Institute on Drug Abuse | 2023 to 2024 | $1,422,069 | October 1, 2022 | January 31, 2026 | BRADLEY, HEATHER | reporter.nih.gov |
| Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE) | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,415,827 | August 15, 2017 | July 31, 2023 | YOUNG, APRIL MARIE | reporter.nih.gov |
| Intestinal Barrier, Probiotic Bacteria, and the Gut-Liver Axis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,415,174 | March 18, 2019 | December 31, 2024 | MA, THOMAS Y | reporter.nih.gov |
| Dynamics of antigen specific B and Tfh responses during acute and chronic HCV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,411,254 | December 13, 2017 | November 30, 2024 | GRAKOUI, ARASH | reporter.nih.gov |
| Determinants of immunotherapy response in NASH-Hepatocellular carcinoma | NIH | National Cancer Institute | 2023 to 2025 | $1,408,891 | August 4, 2023 | July 31, 2028 | LLOVET, JOSEP M | reporter.nih.gov |
| Hepatic fat accumulation in nonalcoholic fatty liver disease: critical regulation by kisspeptin signaling | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,408,849 | April 30, 2022 | March 31, 2027 | BHATTACHARYA, MOSHMI M | reporter.nih.gov |
| Cell surface receptors promoting hepatitis B virus infection | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,406,502 | July 15, 2020 | April 30, 2024 | LUO, GUANGXIANG GEORGE | reporter.nih.gov |
| Integrating low-cost and versatile technologies to achieve colorimetric HCV and HIV detection from whole blood | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,401,526 | August 15, 2024 | June 30, 2029 | MYERS, DAVID RICHARD | reporter.nih.gov |
| Integrated therapies for alcohol use and ALD (ITAALD) Network -UofL Clinical Center | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $1,401,448 | August 1, 2018 | June 30, 2029 | MCCLAIN, CRAIG J. | reporter.nih.gov |
| Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,386,143 | May 1, 2002 | June 30, 2027 | DIEHL, ANNA MAE ELIZABETH | reporter.nih.gov |
| Transcription cycle regulation by nutrients | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,382,190 | July 15, 2022 | April 30, 2027 | MORRAL, NURIA | reporter.nih.gov |
| A proteomics atlas of HIV/HBV infections for curing HBV | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,381,244 | August 1, 2024 | June 30, 2029 | MICHAILIDIS, ELEFTHERIOS | reporter.nih.gov |
| Targeting hepatic mitochondrial oxidation to treat NAFLD, NASH and type 2 diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,375,819 | January 18, 2024 | December 31, 2028 | SHULMAN, GERALD I | reporter.nih.gov |
| Novel mouse models of hepatitis B virus infection and replication | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,373,666 | June 21, 2024 | April 30, 2029 | LUO, GUANGXIANG GEORGE | reporter.nih.gov |
| Hepatitis C Virus Trafficking in Hepatocytes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,372,358 | March 5, 2019 | February 28, 2025 | RANDALL, GLENN C | reporter.nih.gov |
| SELECTION OF VACCINE ANTIGENS FOR PROTECTION FROM HEPATITIS C VIRUS INFECTION | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,349,865 | July 1, 2020 | April 30, 2026 | RAY, RANJIT | reporter.nih.gov |
| Development of a Machine Learning Model to Integrate Clinical, Laboratory, Sonographic, and Elastographic Data for Noninvasive Liver Tissue Characterization in NAFLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,345,263 | January 20, 2019 | December 31, 2025 | SAMIR, ANTHONY EDWARD | reporter.nih.gov |
| Project ACCESS: Advancing Access to HIV/HCV Testing Through Transformation in Syringe Services Programs: A Cluster Randomized Trial | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,343,426 | July 1, 2024 | April 30, 2029 | BARTHOLOMEW, TYLER SCOTT | reporter.nih.gov |
| Liver fibrosis cell-based assay platform: integrating patient-derived fibrotic liver ECM with primary stellate cells, Kupffer cells, and hepatocytes to accelerate anti-fibrotic drug development | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,337,735 | September 1, 2024 | August 31, 2027 | O'NEILL, JOHN DAVID | reporter.nih.gov |
| Viral Determinants of Chronic Hepacivirus Infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,331,080 | June 1, 2024 | April 30, 2029 | KAPOOR, AMIT | reporter.nih.gov |
| Dissecting the Intracellular and Extracellular Role of TREM2 in the Pathogenesis of Non-Alcoholic Steatohepatitis. | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,326,264 | August 15, 2023 | June 30, 2027 | DHAR, DEBANJAN | reporter.nih.gov |
| 2/4-The INTEGRATE Study: Evaluating INTEGRATEd care to Improve Biopschosocial Outcomes of Early Liver Transplantation for Alcohol-Associated Liver Disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2025 | $1,314,963 | August 1, 2023 | July 31, 2030 | VERNA, ELIZABETH CLARICE | reporter.nih.gov |
| Molecular Mechanisms by which Statins Prevent and Reverse Hepatocellular Carcinoma | NIH | National Cancer Institute | 2023 to 2025 | $1,310,295 | September 19, 2023 | August 31, 2027 | FELSHER, DEAN W | reporter.nih.gov |
| Sympathetic circadian dysfunction in obesity-related hepatocarcinogenesis | NIH | National Cancer Institute | 2021 to 2023 | $1,308,596 | September 1, 2019 | August 31, 2025 | FU, LONING NONE | reporter.nih.gov |
| Hepatitis B virus integrations in KMT2B drive hepatocellular carcinoma | NIH | National Cancer Institute | 2023 to 2025 | $1,297,237 | July 15, 2022 | June 30, 2027 | CAO, JIAN | reporter.nih.gov |
| T cells in HCV/HIV co-infection | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,296,998 | March 1, 2018 | December 31, 2023 | LAUER, GEORG MICHAEL | reporter.nih.gov |
| Molecular mechanisms of post-transplant recurrent alcoholic liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $1,286,113 | September 10, 2017 | March 31, 2028 | CARR, ROTONYA M | reporter.nih.gov |
| 1/4-The INTEGRATE Study: Evaluating INTEGRATEd Care to Improve Biopsychosocial Outcomes of Early Liver Transplantation for Alcohol-Associated Liver Disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2025 | $1,276,071 | August 1, 2023 | July 31, 2030 | VANWAGNER, LISA B | reporter.nih.gov |
| Modeling and Characterization of NAFLD Phenotypes in a Severely Affected Family | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,272,904 | February 1, 2024 | November 30, 2027 | MATTIS, ARAS NIKODEMAS | reporter.nih.gov |
| Dysregulated Oxalate Metabolism in Cardiometabolic Diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,269,041 | August 5, 2023 | May 31, 2027 | ROM, OREN | reporter.nih.gov |
| Collaborative Clinical Research in Nonalcoholic Steatohepatitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,268,720 | May 20, 2002 | June 30, 2027 | CHALASANI, NAGA P | reporter.nih.gov |
| Mitochondrial DAMPs-driven Mechanisms of Liver Fibrosis in NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,267,548 | April 1, 2024 | January 31, 2028 | POPOV, YURY | reporter.nih.gov |
| TARGETING MASH WITH NOVEL SMALL MOLECULE TXNIP INHIBITOR | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,264,958 | August 1, 2024 | May 31, 2029 | SHALEV, ANATH | reporter.nih.gov |
| Reducing morbidity and mortality from overdose, HIV, and hepatitis C in opioid-using persons | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,262,543 | September 1, 2018 | June 30, 2024 | BRAITHWAITE, RONALD SCOTT | reporter.nih.gov |
| Role of Human Apolipoprotein E in Hepatitis B Virus Infection and Morphogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,261,056 | September 22, 2020 | August 31, 2024 | LUO, GUANGXIANG GEORGE | reporter.nih.gov |
| Helicobacter Infection and Liver Cancer Risk among African Americans and Whites in the United States | NIH | National Cancer Institute | 2021 to 2023 | $1,249,102 | July 16, 2021 | February 29, 2024 | ZHANG, XUEHONG | reporter.nih.gov |
| Multiparametric ultrasound imaging for early detection of nonalcoholic fatty liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,245,041 | December 21, 2020 | July 31, 2023 | HOYT, KENNETH | reporter.nih.gov |
| Collaborative Integration of Hepatitis B Molecular Virology and Mathematical/Computational Modeling | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,242,317 | January 15, 2019 | June 30, 2025 | UPRICHARD, SUSAN L. | reporter.nih.gov |
| HIV, HCV, Hippo, and Liver Disease Progression | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,239,696 | November 3, 2017 | October 31, 2024 | CHUNG, RAYMOND T | reporter.nih.gov |
| Mechanisms of Early-life Immunity Associated with HIV-1 Vaccine-induced Neutralizing Antibody Responses | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,239,565 | August 20, 2025 | June 30, 2030 | WILLIAMS, WILTON B | reporter.nih.gov |
| Persistent hepatitis C virus replication and immunity in pregnancy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,233,787 | February 1, 2012 | May 31, 2025 | WALKER, CHRISTOPHER M. | reporter.nih.gov |
| Regulation of the pro-fibrotic connective tissue growth factor in alcoholic liver disease: mechanisms and targeting approaches | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $1,233,061 | February 1, 2020 | January 31, 2026 | PI, LIYA | reporter.nih.gov |
| Leveraging HIV care infrastructure for implementation of context-adapted liver cancer comprehensive control strategies in Uganda: The LC3 Study | NIH | National Cancer Institute | 2024 to 2025 | $1,232,605 | September 3, 2024 | August 31, 2029 | KIRK, GREGORY D | reporter.nih.gov |
| Role of Fbxo48-mediated AMPK proteostasis in the pathogenesis and treatment of NAFLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,232,144 | January 1, 2019 | December 31, 2024 | JURCZAK, MICHAEL J. | reporter.nih.gov |
| Manipulation of lipid metabolism in (+)RNA virus replication | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,230,000 | June 7, 2023 | May 31, 2028 | RANDALL, GLENN C | reporter.nih.gov |
| Cyanobacteria, cyanotoxins, and liver cancer development | NIH | National Cancer Institute | 2024 to 2025 | $1,227,270 | May 1, 2024 | April 30, 2029 | HERNANDEZ, BRENDA YUKARI | reporter.nih.gov |
| Exposome and Precision Medicine in NAFLD | NIH | National Institute of Environmental Health Sciences | 2021 to 2022 | $1,217,227 | August 28, 2020 | July 31, 2025 | CAVE, MATTHEW C | reporter.nih.gov |
| A Multi-site Multi-Setting RCT of Integrated HIV Prevention and HCV Care for PWID | NIH | National Institute on Drug Abuse | 2022 | $1,217,167 | September 30, 2017 | March 12, 2025 | METSCH, LISA R | reporter.nih.gov |
| Novel IP6K1 inhibitors for treatment of NAFLD/NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,215,396 | April 1, 2024 | January 31, 2028 | WANG, XIAODONG | reporter.nih.gov |
| Hepatic Integration of Mitochondrial Oxidative Metabolism Pathways in Health and Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,214,419 | July 1, 2023 | April 30, 2028 | HUGHEY, CURTIS | reporter.nih.gov |
| Active HCV diagnosis to support prevention of HCC in LMICs | NIH | National Cancer Institute | 2024 to 2025 | $1,208,204 | August 9, 2024 | July 31, 2029 | MCFALL, SALLY MAUREEN | reporter.nih.gov |
| Interleukin 33 Regulation for Cancer Prevention in Chronic Inflammation | NIH | National Cancer Institute | 2024 to 2025 | $1,208,126 | April 1, 2024 | March 31, 2029 | DEMEHRI, SHADMEHR | reporter.nih.gov |
| 2/4-American Consortium of Early Liver Transplantation-Prospective Alcohol-associated liver disease Cohort Evaluation (ACCELERATE-PACE) | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2025 | $1,205,015 | August 17, 2023 | July 31, 2030 | SERPER, MARINA | reporter.nih.gov |
| A chicken model to study hepatitis E virus pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,200,000 | June 15, 2002 | April 30, 2025 | MENG, XIANG-JIN | reporter.nih.gov |
| The role of hexokinase 2 in liver fibrosis and NASH-induced HCC | NIH | National Cancer Institute | 2024 to 2025 | $1,194,448 | September 1, 2024 | August 31, 2029 | HAY, NISSIM | reporter.nih.gov |
| Mechanisms Underlying the Pathogenesis of Non-alcoholic Fatty Liver Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2024 | $1,193,434 | July 1, 2015 | August 31, 2024 | ZHANG, YANQIAO | reporter.nih.gov |
| A Cluster RCT to Increase HIV Testing in Substance Use Treatment Programs | NIH | National Institute on Drug Abuse | 2021 | $1,188,364 | September 1, 2016 | July 31, 2025 | METSCH, LISA R | reporter.nih.gov |
| 3/4-The INTEGRATE Study: Evaluating INTEGRATEd Care to Improve Biopsychosocial Outcomes of Early Liver Transplantation for Alcohol-Associated Liver Disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2025 | $1,185,356 | August 10, 2023 | July 31, 2030 | GOLDBERG, DAVID SETH | reporter.nih.gov |
| Epitranscriptomic regulation of HBV gene expression | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,184,583 | March 1, 2019 | February 29, 2024 | SIDDIQUI, ALEEM | reporter.nih.gov |
| Quantitative characterization of the liver-pancreas axis in diabetes via multiparametric magnetic resonance elastography | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,181,482 | August 9, 2023 | April 30, 2028 | YIN, MENG | reporter.nih.gov |
| Development and Preclinical Evaluation of Nanoformulations in Liver Fibrotic Mice | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,177,172 | April 1, 2023 | February 29, 2028 | MAHATO, RAM I. | reporter.nih.gov |
| Developmental regulation of HBV biosynthesis by Ten-eleven translocation (Tet) methylcytosine dioxygenases | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,173,588 | June 9, 2023 | May 31, 2028 | MCLACHLAN, ALAN | reporter.nih.gov |
| AhR-dependent Pkm2 regulation in NAFLD progression | NIH | National Institute of Environmental Health Sciences | 2021 to 2023 | $1,171,441 | April 1, 2019 | March 31, 2025 | ZACHAREWSKI, TIMOTHY R. | reporter.nih.gov |
| Development of delivery methods for combination microRNA treatment of alcohol-associated liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2023 | $1,167,111 | July 1, 2019 | June 30, 2025 | OUPICKY, DAVID | reporter.nih.gov |
| 3/4-American Consortium of Early Liver Transplantation-Prospective Alcohol-associated liver disease Cohort Evaluation (ACCELERATE-PACE) | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2025 | $1,166,224 | August 17, 2023 | July 31, 2030 | LUCEY, MICHAEL RONAN | reporter.nih.gov |
| Testing of a Novel Inhaled Clofazimine (CFZ) Dry Powder Formulation in a Mouse Model of Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,164,080 | August 1, 2023 | June 30, 2025 | ENDSLEY, JANICE | reporter.nih.gov |
| Mechanisms regulating lipoprotein secretion and lipid metabolism | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,157,766 | January 1, 2023 | December 31, 2026 | NI, HONGMIN | reporter.nih.gov |
| Oral digoxin for the treatment of NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,157,605 | March 15, 2024 | January 31, 2029 | BANINI, BUBU AMA | reporter.nih.gov |
| RNA m6A methylation contributes to hepatic inflammation in obesity-associated NAFLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,156,109 | March 1, 2023 | December 31, 2026 | OUYANG, XINSHOU | reporter.nih.gov |
| Effects of State Laws to Reduce Opioid Diversion on Transitions to Injection Drug Use and HIV/HCV Transmission | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,137,366 | April 1, 2018 | December 31, 2023 | DICKSON-GOMEZ, JULIA B | reporter.nih.gov |
| Role of CMA failure in NASH progression to Hepatocellular Carcinoma | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,134,000 | May 1, 2020 | April 30, 2025 | ARIAS-PEREZ, ESPERANZA | reporter.nih.gov |
| Drug Injection Surveillance and Care Enhancement for Rural Northern New England (DISCERNNE) | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,131,736 | August 15, 2017 | July 31, 2023 | FRIEDMANN, PETER D | reporter.nih.gov |
| Structure-Based Vaccine Design for Hepatits C Virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,120,994 | June 1, 2017 | May 31, 2023 | FUERST, THOMAS R | reporter.nih.gov |
| Impact of HIV co-infections and comorbidities on circadian rhythm in the liver | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,120,539 | August 15, 2024 | May 31, 2029 | MICHAILIDIS, ELEFTHERIOS | reporter.nih.gov |
| 4/4-American Consortium of Early Liver Transplantation-Prospective Alcohol-associated liver disease Cohort Evaluation (ACCELERATE-PACE) | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2025 | $1,116,244 | August 1, 2023 | July 31, 2030 | GHOBRIAL, RAFIK MARK | reporter.nih.gov |
| Harnessing big data to arrest the HIV/HCV/opioid syndemic in the rural and urban South | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,115,625 | June 1, 2023 | March 31, 2028 | REBEIRO, PETER F | reporter.nih.gov |
| How does a metallofactor in Hepatitis B viral protein X orchestrate pathogenesis and liver cancer | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $1,115,277 | July 5, 2019 | June 30, 2024 | PANDELIA, MARIA-EIRINI | reporter.nih.gov |
| Innate Immunity, Cholesterol, and NASH Pathogenesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,113,750 | January 20, 2020 | June 30, 2025 | GOLDEN, LUCY MARY | reporter.nih.gov |
| Impact of preanalytic procurement and processing variables on the detection of HCC DNA in urine | NIH | National Cancer Institute | 2023 to 2025 | $1,112,955 | February 1, 2023 | January 31, 2028 | SU, YING-HSIU | reporter.nih.gov |
| Non-invasive screening of diabetics for advanced fibrosis due to NAFLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $1,109,857 | May 20, 2020 | April 30, 2025 | LOOMBA, ROHIT | reporter.nih.gov |
| The role of neutralizing antibodies in natural and treatment-induced control of hepatitis B with and without HIV-1 co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,101,905 | January 24, 2023 | December 31, 2027 | BAILEY, JUSTIN RICHARD | reporter.nih.gov |
| Role of Sensory Innervation in High Fat Diet-Induced Hepatotoxicity | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2023 | $1,100,189 | April 1, 2022 | April 25, 2024 | ALPINI, GIANFRANCO D | reporter.nih.gov |
| Roles for microRNA-122 and circular RNAs in flavivirus RNA amplification | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,099,000 | February 15, 2006 | April 30, 2025 | SARNOW, PETER | reporter.nih.gov |
| Aryl hydrocarbon receptor-mediated differential gene regulation - Mechanism of stanniocalcin 2 mediated protection against NAFLD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,098,375 | July 12, 2019 | February 28, 2025 | JOSHI, ADITYA D | reporter.nih.gov |
| Tracking HIV Infection & Alcohol Abuse CNS Comorbidity with Neuroimaging | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 | $1,088,145 | September 30, 2007 | August 31, 2023 | PFEFFERBAUM, ADOLF | reporter.nih.gov |
| The Role of p53-R249S’s GOF in HCC development | NIH | National Cancer Institute | 2021 to 2023 | $1,072,557 | January 1, 2019 | December 31, 2024 | LU, HUA | reporter.nih.gov |
| The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for HCV Trial | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,050,850 | March 1, 2018 | December 31, 2024 | HAUKOOS, JASON | reporter.nih.gov |
| Nuclear envelope and predisposition to hepatic neoplasia | NIH | National Cancer Institute | 2023 to 2025 | $1,049,504 | August 1, 2023 | July 31, 2028 | SHIN, JI-YEON | reporter.nih.gov |
| Nuclear Envelope, Lipoprotein Metabolism, and Hepatic Steatosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $1,048,784 | April 10, 2019 | March 31, 2024 | WORMAN, HOWARD J | reporter.nih.gov |
| Organoid-guided Precision Hepatology for Steatohepatitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,046,027 | February 15, 2024 | December 31, 2028 | TAKEBE, TAKANORI | reporter.nih.gov |
| Defining Phenotypes of Alcohol-Associated Liver Disease with Acute Hepatic Decompensation | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $1,043,280 | June 10, 2021 | May 31, 2026 | KWONG, ALLISON | reporter.nih.gov |
| The mitochondrial aspects of health disparity of hepatocellular carcinoma in Hispanic population | NIH | National Cancer Institute | 2023 to 2025 | $1,040,371 | July 1, 2023 | June 30, 2026 | BAI, YIDONG | reporter.nih.gov |
| DAMPs and Their Receptors Link Hepatocyte Death to HSC Activation and Liver Fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $1,039,942 | September 20, 2019 | July 31, 2023 | SCHWABE, ROBERT F. | reporter.nih.gov |
| Individual, Network and Spatial Drivers of HIV and HCV among PWID in India | NIH | National Institute on Drug Abuse | 2021 | $1,035,149 | September 1, 2016 | May 31, 2023 | SOLOMON, SUNIL SUHAS | reporter.nih.gov |
| Deciphering the role of TREM2 in Non-Alcoholic Steatohepatitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,031,888 | April 1, 2023 | January 31, 2028 | LIANG, SHUANG | reporter.nih.gov |
| Regulation and Function of Thioredoxin Interacting Protein (Txnip) in Nonalcoholic Steatohepatitis (NASH) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,026,745 | July 1, 2023 | April 30, 2028 | YANG, LING | reporter.nih.gov |
| An innovative, non-thiazolidinedione pan-PPAR agonist therapeutic for alcoholic hepatitis: IND-enabling safety and toxicological evaluation | NIH | National Institute on Alcohol Abuse and Alcoholism | 2025 | $1,025,643 | May 15, 2022 | April 30, 2027 | MANCHEM, PRASAD | reporter.nih.gov |
| Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,014,677 | May 20, 2002 | June 30, 2027 | SANYAL, ARUN J | reporter.nih.gov |
| Epigenetic Heterogeneity as a Driver of Liver Disease and Cancer | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2022 | $1,012,300 | August 15, 2018 | May 31, 2024 | ROBERTSON, KEITH D | reporter.nih.gov |
| Targeting Uric Acid as a Therapeutic for NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,010,541 | May 1, 2020 | February 28, 2025 | KHOO, NICHOLAS | reporter.nih.gov |
| NAFLD Diagnosis and Outcomes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,007,669 | February 15, 2024 | December 31, 2028 | ALLEN, ALINA M | reporter.nih.gov |
| Implementing a Community-Based Response to the Opioid Epidemic in Rural Ohio - Supplement | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,004,587 | August 15, 2017 | July 31, 2023 | MILLER, WILLIAM C | reporter.nih.gov |
| Genetic and Environmental risk of NAFLD-related HCC In All Latinos: the GENIAL Study | NIH | National Cancer Institute | 2023 to 2025 | $1,000,316 | September 21, 2023 | August 31, 2027 | JONES, PATRICIA DENISE | reporter.nih.gov |
| Hepatoselective Dihydrozuinolizone (HS-DHQ) Molecules for Treatment and Prevention of Hepatitis A Virus (HAV) Infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,000,000 | April 10, 2023 | July 31, 2027 | DU, YANMING | reporter.nih.gov |
| Hepatic FOXA3 Links NAFLD to Atherosclerosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $996,287 | April 1, 2019 | March 31, 2025 | ZHANG, YANQIAO | reporter.nih.gov |
| Advancing a novel potent double anti-HCV nucleoside analog combination treatment for the OUD population to the clinic | NIH | National Institute on Drug Abuse | 2021 | $995,102 | September 15, 2019 | August 31, 2023 | KLUMPP, KLAUS | reporter.nih.gov |
| Novel insulin-sensitizing NASH/diabetes drugs. | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $995,052 | September 17, 2019 | August 31, 2023 | PETERSON, TIMOTHY R | reporter.nih.gov |
| Novel Paxillin-FAK Inhibitors for the Treatment of Liver Fibrosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $989,753 | September 15, 2024 | August 31, 2028 | MARLOWE, TIMOTHY A | reporter.nih.gov |
| A preclinical multi-modal system for dynamic noninvasive assessment of liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $989,080 | September 20, 2016 | February 29, 2024 | CZERNUSZEWICZ, TOMASZ JOSEPH | reporter.nih.gov |
| Development of a Novel MRI Contrast Agent for Early Detection of Alcoholic Steatohepatitis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 | $984,309 | September 20, 2020 | February 28, 2023 | YANG, JENNY J. | reporter.nih.gov |
| Ubiquitin D as a potential therapeutic target for NASH, HCC and chronic kidney diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $980,000 | August 1, 2023 | May 31, 2028 | DHAR, DEBANJAN | reporter.nih.gov |
| (PQ6)Nuclear receptor mechanisms in circadian disruption induced hepatocarcinogenesis | NIH | National Cancer Institute | 2021 to 2022 | $967,903 | September 18, 2018 | August 31, 2024 | FU, LONING NONE | reporter.nih.gov |
| qHTS of Patient Derived HCC Models to Identify Novel Probes/Therapeutic Agents | NIH | National Cancer Institute | 2021 to 2022 | $964,654 | March 1, 2019 | August 31, 2023 | JOHNSTON, PAUL A. | reporter.nih.gov |
| Host response and liver disease in a hepatitis C-like virus rat model | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $964,504 | February 1, 2018 | January 31, 2024 | KAPOOR, AMIT | reporter.nih.gov |
| Early detection of HCC using noninvasive activity-based nanosensors | NIH | National Cancer Institute | 2021 | $964,382 | June 1, 2019 | July 31, 2023 | WINCKLER, WENDY | reporter.nih.gov |
| Accurate Point of Care Liver Disease Diagnostics, Phase II | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $947,354 | September 30, 2022 | June 30, 2027 | PRADO, PABLO J | reporter.nih.gov |
| Vertical Sleeve Gastrectomy for Treatment of NASH: a pilot randomized control | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $946,907 | July 14, 2021 | May 31, 2025 | IKRAMUDDIN, SAYEED | reporter.nih.gov |
| Community-based, client-centered prevention homes to address the rural opioid epidemic | NIH | National Institute on Drug Abuse | 2021 to 2022 | $941,278 | August 15, 2017 | July 31, 2023 | WESTERGAARD, RYAN PATRICK | reporter.nih.gov |
| Resolution of nonalcoholic fatty liver and nonalcoholic steatohepatitis by a novel adipokine | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $938,470 | September 1, 2024 | June 30, 2026 | WANG, YONG-XU | reporter.nih.gov |
| California Hub for HIV/STI/SUD Prevention Research with Reentry Populations | NIH | National Institute on Drug Abuse | 2025 | $932,421 | May 15, 2024 | July 31, 2029 | HARAWA, NINA THAWATA | reporter.nih.gov |
| Innate Immunity in NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2024 | $929,006 | July 1, 2023 | April 30, 2027 | BAI, JULI | reporter.nih.gov |
| Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $919,166 | June 15, 2002 | June 30, 2027 | TERRAULT, NORAH A. | reporter.nih.gov |
| The Role of HBeAg in HBV Persistence | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $907,565 | August 10, 2018 | June 30, 2030 | GUO, HAITAO | reporter.nih.gov |
| C-Type Lectins and Immune Surveillance in ALD | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2024 | $892,164 | September 1, 2022 | August 31, 2025 | KIM, ADAM | reporter.nih.gov |
| Rapid point of care Hepatitis C virus detection using a long-lasting luminescent cascade signal amplification | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $884,453 | November 22, 2024 | October 31, 2029 | SHAFIEE, HADI | reporter.nih.gov |
| Novel Hepatitis B Vaccine and Immunotherapy | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $883,119 | August 21, 2024 | July 31, 2025 | LAW, MANSUN | reporter.nih.gov |
| Specific-sized hyaluronan: a dual targeted therapy for ALD | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2022 | $880,703 | August 1, 2018 | July 31, 2025 | NAGY, LAURA E. | reporter.nih.gov |
| Nutrient Overload, Insulin Resistance, and Hepatic Mitochondrial Dysfunction | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $878,892 | July 1, 2017 | April 30, 2023 | PARKS, ELIZABETH JANE | reporter.nih.gov |
| Extracellular Vesicles in Alcoholic Liver Disease: Basic and Pre-Clinical Discovery | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2022 | $868,947 | July 1, 2020 | December 31, 2024 | SZABO, GYONGYI | reporter.nih.gov |
| Mechanisms of parvovirus replication in viral hepatitis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $868,900 | August 12, 2022 | July 31, 2027 | JAGER, MASON CAMERON | reporter.nih.gov |
| HBV cccDNA and integrated DNA in HIV coinfection and HBV monoinfection | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $847,428 | August 3, 2023 | July 31, 2025 | LAU, DARYL T | reporter.nih.gov |
| The Landscape of Serious Infections following Kidney Transplantation in People Living with HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $846,608 | August 19, 2021 | July 31, 2026 | WERBEL, WILLIAM | reporter.nih.gov |
| Role of TLR7 in progression and treatment of alcoholic hepatitis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2022 | $846,006 | September 1, 2018 | December 31, 2024 | SEKI, EKIHIRO | reporter.nih.gov |
| Antiviral prophylaxis and infant vaccination to prevent perinatal hepatitis B infection | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $842,795 | February 15, 2018 | January 31, 2025 | JOURDAIN, GONZAGUE JOSEPH | reporter.nih.gov |
| The role of NLRP6 and DHX15 in control of infection by RNA viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $837,500 | January 1, 2018 | December 31, 2023 | FIKRIG, EROL | reporter.nih.gov |
| Ataxia Telangiectasia Mutated (ATM)-mediated hepatic DNA damage in pediatric nonalcoholic fatty liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $837,420 | September 1, 2021 | July 31, 2026 | VISWANATHAN, PREETI | reporter.nih.gov |
| Neutrophil elastase in obesity-related fatty liver diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $831,723 | September 15, 2020 | August 31, 2025 | JIANG, ZHEN YUE | reporter.nih.gov |
| Novel hyperpolarized 13C molecular imaging techniques for differentiating NAFLD and NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $831,004 | September 20, 2018 | August 31, 2025 | OHLIGER, MICHAEL | reporter.nih.gov |
| Fat and Iron-Corrected Quantitative MRI T1 Mapping for Evaluation of Chronic Liver Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $830,401 | September 15, 2025 | July 31, 2030 | FENG, LI | reporter.nih.gov |
| Role of cholecystokinin receptor in hepatocellular cancer | NIH | National Cancer Institute | 2021 to 2025 | $814,845 | September 1, 2021 | August 31, 2026 | GAY, MARTHA | reporter.nih.gov |
| Immune analysis of the HBsAg seroclearance response terminating chronic HBV | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $814,790 | November 20, 2024 | October 31, 2029 | BARON, JODY L | reporter.nih.gov |
| California Hub for HIV/STI/SUD Prevention Research with Reentry Populations | NIH | National Institute on Drug Abuse | 2024 | $814,282 | May 15, 2024 | April 30, 2026 | HARAWA, NINA THAWATA | reporter.nih.gov |
| The Unfolded Protein Response in Fatty Liver | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $810,996 | July 1, 2019 | March 31, 2024 | GREEN, RICHARD M | reporter.nih.gov |
| Mechanisms of HBV cccDNA transcriptional regulation in persons with and without HIV | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $810,981 | August 14, 2018 | July 31, 2025 | BALAGOPAL, ASHWIN | reporter.nih.gov |
| Spatial omics to understanding HBV control in people with HIV coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $806,208 | September 4, 2025 | August 31, 2030 | SCHWARTZ, ROBERT E | reporter.nih.gov |
| Characterizing Hepatitis B Transmission in Congolese Children | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $803,494 | June 23, 2020 | May 31, 2026 | THOMPSON, PEYTON J | reporter.nih.gov |
| Establishing the mechanism of benefit and dose of exercise required to improve liver histology in patients with nonalcoholic steatohepatitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $800,540 | February 1, 2022 | June 27, 2025 | STINE, JONATHAN G | reporter.nih.gov |
| DAT 18-06 Feasibility and Acceptability of HIV, HCV, and Opioid Use Disorder Services in Syringe Service Programs | NIH | National Institute on Drug Abuse | 2021 | $800,234 | September 1, 2009 | July 31, 2022 | SCHACKMAN, BRUCE R | reporter.nih.gov |
| Proteogenomics-driven therapeutic discovery in hepatocellular carcinoma | NIH | National Cancer Institute | 2021 to 2024 | $797,641 | April 1, 2020 | March 31, 2026 | ZHANG, BING | reporter.nih.gov |
| HCV Ghost Sequencing Center | NIH | National Institute on Drug Abuse | 2021 to 2022 | $795,218 | August 15, 2017 | July 31, 2023 | ALLEN, TODD M | reporter.nih.gov |
| Mechanisms of gut microbiota/metabolite interface-mediated hepatic inflammation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2023 | $794,466 | August 15, 2022 | April 18, 2024 | LI, GUANGFU | reporter.nih.gov |
| Helicobacter Infection and Liver Cancer Risk among African Americans and Whites in the United States | NIH | National Cancer Institute | 2024 to 2025 | $793,720 | July 16, 2021 | August 31, 2026 | ZHANG, XUEHONG | reporter.nih.gov |
| Candidate Selection for Liver Transplantation in Patients with Alcohol-related Liver Disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $792,720 | July 1, 2020 | June 30, 2026 | CHEN, PO-HUNG (VICTOR) | reporter.nih.gov |
| A vascularized patient-derived iPSC liver acinus microphysiology system as an innovative precision medicine platform for optimizing clinical trial design for nonalcoholic fatty liver disease | NIH | National Center for Advancing Translational Sciences | 2021 | $791,956 | July 15, 2020 | June 30, 2022 | TAYLOR, D. LANSING | reporter.nih.gov |
| A gerbil model to delineate the mechanism of hepatitis E virus extrahepatic pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $788,000 | November 9, 2023 | October 31, 2028 | MENG, XIANG-JIN | reporter.nih.gov |
| Structural Basis for Antiviral Drug Mitochondrial Toxicity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $782,460 | March 1, 2018 | February 28, 2025 | YIN, YUHUI | reporter.nih.gov |
| Point-of-care magnetofluidic HCV diagnostic using thermally responsive valves | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $781,351 | March 1, 2024 | January 31, 2028 | WHITE, IAN M | reporter.nih.gov |
| Characterization of silently HBV-infected hepatocytes in HIV co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $779,416 | August 14, 2018 | July 31, 2023 | BALAGOPAL, ASHWIN | reporter.nih.gov |
| Myeloid FoxO1 in Lipid Metabolism | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $778,948 | August 1, 2019 | July 31, 2024 | DONG, HENGJIANG HENRY | reporter.nih.gov |
| Adaptive Liver Tolerance via LSECs | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $777,500 | September 19, 2018 | August 31, 2023 | CRISPE, IAN NICHOLAS | reporter.nih.gov |
| A Hybrid Implementation-Effectiveness Study of the Pharmacist, Physician, and Patient Navigator Collaborative Care Model to cure Hepatitis C among persons who use drugs with housing insecurity | NIH | National Institute on Drug Abuse | 2025 | $777,497 | August 15, 2025 | April 30, 2030 | TSUI, JUDITH | reporter.nih.gov |
| Human factors-designed triple test for HIV, HBV, and HCV infection in whole blood using target amplification, signal amplification, and crumpled graphene biosensor readout | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $776,341 | September 16, 2025 | August 31, 2030 | CUNNINGHAM, BRIAN T. | reporter.nih.gov |
| Mechanisms of mitochondrial dynamics, quality control and mtDNA-mediated inflammation in alcohol-associated liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2024 to 2025 | $772,738 | August 20, 2024 | May 31, 2029 | DING, WEN-XING | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| University of California Los Angeles | Los Angeles, CA | 14 | $568.6 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 42 | $114.7 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 28 | $60.3 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 25 | $49.5 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 23 | $45 million | 0 | $0 |
| Yale University | New Haven, CT | 24 | $38.5 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 18 | $31.1 million | 0 | $0 |
| Duke University | Durham, NC | 9 | $30.6 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 7 | $30.6 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 10 | $30.1 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 15 | $21.8 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 22 | $21.7 million | 0 | $0 |
| University of Louisville | Louisville, KY | 15 | $20.7 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 18 | $20 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 15 | $19.6 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 19 | $17.9 million | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 5 | $17.9 million | 0 | $0 |
| Universitat Bern | Bern | 1 | $16.8 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 4 | $16.8 million | 0 | $0 |
| Stanford University | Stanford, CA | 14 | $16.6 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 9 | $15.5 million | 0 | $0 |
| Oklahoma Medical Research Foundation | Oklahoma City, OK | 1 | $15.2 million | 0 | $0 |
| Cleveland Clinic Lerner Com-Cwru | Cleveland, OH | 11 | $14.7 million | 0 | $0 |
| Research Inst Nationwide Children's Hosp | Columbus, OH | 13 | $14.5 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 12 | $13.8 million | 0 | $0 |
| Emory University | Atlanta, GA | 16 | $12.5 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 7 | $12.4 million | 0 | $0 |
| North Carolina State University | Raleigh, NC | 2 | $12.3 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 9 | $11.8 million | 0 | $0 |
| Rockefeller University | New York, NY | 7 | $11.8 million | 0 | $0 |
| University of Kentucky | Lexington, KY | 5 | $11.7 million | 0 | $0 |
| University of Washington | Seattle, WA | 10 | $11.5 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 11 | $11.3 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 5 | $10.9 million | 0 | $0 |
| Loyola University Chicago | Maywood, IL | 6 | $10.9 million | 0 | $0 |
| Scripps Research Institute, the | La Jolla, CA | 7 | $10.8 million | 0 | $0 |
| Beth Israel Deaconess Medical Center | Boston, MA | 13 | $10.8 million | 0 | $0 |
| American Type Culture Collection | Manassas, VA | 1 | $10.7 million | 0 | $0 |
| Saint Louis University | Saint Louis, MO | 8 | $10.7 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 7 | $10.4 million | 0 | $0 |
| Wake Forest University Health Sciences | Winston-Salem, NC | 7 | $10.2 million | 0 | $0 |
| Virginia Commonwealth University | Richmond, VA | 9 | $10.2 million | 0 | $0 |
| Chiang Mai University | Chiang Mai | 1 | $10.1 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 7 | $9.9 million | 0 | $0 |
| University of Missouri-Columbia | Columbia, MO | 4 | $9.5 million | 0 | $0 |
| University of Kansas Medical Center | Kansas City, KS | 11 | $9.1 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 4 | $9.1 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 9 | $9 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 7 | $8.5 million | 0 | $0 |
| University of Maryland, College Park | College Park, MD | 5 | $8.3 million | 0 | $0 |
| Fundacao Oswaldo Cruz | Rio de Janeiro | 1 | $8.2 million | 0 | $0 |
| University of Chicago | Chicago, IL | 5 | $7.9 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 8 | $7.9 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 6 | $7.7 million | 0 | $0 |
| University of Texas Med BR Galveston | Galveston, TX | 6 | $7.5 million | 0 | $0 |
| Princeton University | Princeton, NJ | 4 | $7.3 million | 0 | $0 |
| University of Florida | Gainesville, FL | 8 | $7.2 million | 0 | $0 |
| Pennsylvania State Univ Hershey Med CTR | Hershey, PA | 6 | $7.1 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 5 | $6.8 million | 0 | $0 |
| Georgia State University | Atlanta, GA | 3 | $6.3 million | 0 | $0 |
| Cedars-Sinai Medical Center | Los Angeles, CA | 4 | $6.2 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 2 | $6.1 million | 0 | $0 |
| Georgetown University | Washington, DC | 7 | $5.8 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 3 | $5.8 million | 0 | $0 |
| University of Oklahoma HLTH Sciences CTR | Oklahoma City, OK | 5 | $5.7 million | 0 | $0 |
| University of Nebraska Medical Center | Omaha, NE | 5 | $5.5 million | 0 | $0 |
| Triad National Security, LLC | Los Alamos, NM | 2 | $5.5 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 4 | $5.2 million | 0 | $0 |
| Ohio State University | Columbus, OH | 7 | $5.1 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 4 | $4.8 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 2 | $4.8 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 6 | $4.6 million | 0 | $0 |
| Northern California Institute/res/edu | San Francisco, CA | 1 | $4.6 million | 0 | $0 |
| Imcare Biotech, Inc. | Doylestown, PA | 3 | $4.5 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 5 | $4.5 million | 0 | $0 |
| University of Hawaii | Honolulu, HI | 2 | $4.5 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 5 | $4.4 million | 0 | $0 |
| Virginia Polytechnic Institute and State University | Blacksburg, VA | 4 | $4.3 million | 0 | $0 |
| Temple Univ of the Commonwealth | Philadelphia, PA | 2 | $4.2 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 2 | $3.8 million | 0 | $0 |
| Ohio University | Athens, OH | 3 | $3.8 million | 0 | $0 |
| Starks Associates, Inc. | Buffalo, NY | 1 | $3.7 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 2 | $3.7 million | 0 | $0 |
| California Pacific Med CTR Res Institute | San Francisco, CA | 1 | $3.6 million | 0 | $0 |
| Northeast Ohio Medical University | Rootstown, OH | 5 | $3.5 million | 0 | $0 |
| Venatorx Pharmaceuticals, Inc. | Malvern, PA | 2 | $3.5 million | 0 | $0 |
| New York University | New York, NY | 1 | $3.4 million | 0 | $0 |
| University of Texas at Austin | Austin, TX | 2 | $3.3 million | 0 | $0 |
| Michigan State University | East Lansing, MI | 2 | $3.3 million | 0 | $0 |
| Louisiana State Univ HSC Shreveport | Shreveport, LA | 4 | $3.2 million | 0 | $0 |
| Feinstein Institute for Medical Research | Manhasset, NY | 2 | $3.2 million | 0 | $0 |
| Translational Genomics Research Inst | Phoenix, AZ | 1 | $3.2 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 2 | $3.1 million | 0 | $0 |
| Carogen Corporation | Hamden, CT | 1 | $3 million | 0 | $0 |
| Gryphon Scientific, LLC | Takoma Park, MD | 1 | $3 million | 0 | $0 |
| Washington University | Saint Louis, MO | 4 | $3 million | 0 | $0 |
| Harvard University D/b/a Harvard School of Public Health | Boston, MA | 1 | $2.9 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 4 | $2.9 million | 0 | $0 |
| Indiana University | Bloomington, IN | 3 | $2.8 million | 0 | $0 |
| Hbvtech | Germantown, MD | 5 | $2.7 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 421 | $338,213,864 | 0 | $0 |
| 2024 | 465 | $319,037,423 | 0 | $0 |
| 2023 | 472 | $397,009,196 | 0 | $0 |
| 2022 | 494 | $436,628,578 | 0 | $0 |
| 2021 | 521 | $432,401,599 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.